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Nonfatal Motor-Vehicle Animal Crash–Related Injuries —
United States, 2001–2002
In 2000, an estimated 6.1 million light-vehicle (e.g.,
passenger cars, sport utility vehicles, vans, and pickup trucks)
crashes on U.S. roadways were reported to police (1). Of these
reported crashes, 247,000 (4.0%) involved incidents in which
the motor vehicle (MV) directly hit an animal on the road-
way (1). Each year, an estimated 200 human deaths result
from crashes involving animals (i.e., deaths from a direct MV
animal collision or from a crash in which a driver tried to
avoid an animal and ran off the roadway) (2). To characterize
nonfatal injuries from these incidents, CDC analyzed data
from the National Electronic Injury Surveillance System-All
Injury Program (NEISS-AIP). This report summarizes the
results of that analysis, which indicated that, during 2001–
2002, an estimated 26,647 MV occupants per year were
involved in crashes from encounters with animals (predomi-
nantly deer) in a roadway and treated for nonfatal injuries in
U.S. hospital emergency departments (EDs). Cost-effective
measures targeting both drivers (e.g., speed reduction and early
warnings) and animals (e.g., fencing and underpasses) are
needed to reduce injuries associated with MV collisions
involving animals.
NEISS-AIP is operated by the Consumer Product Safety
Commission and collects data about initial visits for all types
and causes of injuries treated in U.S. EDs (3). NEISS-AIP
data are drawn from a nationally representative subsample of
66 of 100 NEISS-AIP hospitals selected as a stratified prob-
ability sample of hospitals in the United States and its territo-
ries with a minimum of six beds and a 24-hour ED.
NEISS-AIP provides data on approximately 500,000 injury-
and consumer product–related ED cases each year. Data for
each case include a comment variable that contains additional
information about the circumstances of the injury.
Each case was assigned a sample weight on the basis of the
inverse probability of selection; these weights were summed
to provide national estimates of MV animal crash–related
injuries. Confidence intervals (CIs) were calculated by using a
direct variance estimation procedure that accounted for the
sample weights and complex sample design. Rates were calculated
by using 2001 and 2002 U.S. Census bridged-race population
estimates from the National Center for Health Statistics (4).
Data used in this study were obtained from medical records
of 676 ED patients treated for nonfatal injuries incurred while
driving or riding in a light vehicle and encountering an ani-
mal in the roadway. This report focuses on the majority of
these patients, who encountered larger animals (e.g., deer,
moose, elk, bear, horses, or cattle) entering the roadway. Smaller
animals (e.g., dogs, cats, squirrels, raccoons, and possums)
were included only in the overall national estimate. No infor-
mation was obtained on type of vehicle. MV animal crashes
were defined as those involving direct collision with an ani-
mal on a roadway or those occurring on or off the roadway as
a result of trying to avoid hitting the animal. These cases were
identified by using a brief narrative captured in the NEISS-
AIP database that described the circumstances of the injury
incident. An additional 79 patients injured as
motorcyclists involved in MV-animal crashes were excluded
from this study.
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During 2001–2002, an estimated 26,647 (9.3 per 100,000
population; 95% CI = 6.7–11.9) persons were treated annu-
ally in U.S. EDs for MV animal crash–related injuries, of which
22,498 (84.8%) were MV occupants in crashes involving larger
animals (Table 1). The highest MV large animal crash–
related injury rate (21.1 per 100,000 population) occurred
among persons aged 15–24 years (Table 1). The age distribu-
tion of those injured in MV large animal crashes was different
from those injured during all other types of MV traffic-
related crashes (p<0.03); most of this difference was attrib-
uted to an overrepresentation of persons aged 15–24 years
(p<0.0001) and an underrepresentation of children aged 0–14
years (p<0.0001) (Figure). Among injured persons aged 15–24
years, 48.9% were driving the vehicle. The MV large animal
crash–related injury rate was similar for males and females
(Table 1). Approximately 6% of those treated in U.S. EDs
required hospitalization for their injuries.
MV large animal crash–related injuries were mostly strains/
sprains (36.5%) and contusions/abrasions (33.9%) and
involved the head/face (28.1%), neck (22.7%), and upper
trunk (15.3%) (Table 2). The majority (94.5%) of the neck
injuries were strains and sprains, and 62.5% of head/face
injuries were contusions, abrasions, or lacerations. Persons
injured during MV large animal crashes were treated more
often during October and November than other months. Deer
were the most common large animals involved in these
TABLE 1. Estimated annual number, percentage, and rate* of
persons treated in emergency departments for nonfatal motor-
vehicle large animal crash–related injuries, by age, sex, and
disposition — United States, 2001–2002
Estimated
Characteristic no. (%)†   Rate (95% CI§)
Age group (yrs)
0–14      925    (4.1) 1.5 (0.7–2.3)
15–24   8,508  (37.8) 21.1 (14.6–27.6)
25–34   4,793  (21.3) 12.0 (7.0–17.0)
35–44   3,736  (16.6) 8.3 (5.0–11.6)
45–54   2,368  (10.5) 6.0 (3.8–8.2)
>55   2,113 (9.4) 3.4 (2.2–4.6)
Unknown        56¶ (0.2)¶ —
Sex
Male  11,289 (50.2) 8.0 (5.6–10.4)
Female  11,209 (49.8) 7.7 (5.6–9.8)
Disposition
Treated/Released  20,902 (92.9) 7.3 (5.2–9.4)
Hospitalized/
Transferred    1,315 (5.8) 0.5 (0.2–0.8)
Observed      281¶ (1.3)¶ —
Total 22,498 (100.0) 7.8 (5.7–10.0)
* Per 100,000 population.
†




Estimates might be unstable because they are based on <20 NEISS-AIP
cases or coefficient of variation is >30%.
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incidents (86.9%). Approximately half (54.4%) of these
crashes involved a direct collision with the animal, and the
remainder (44.8%) resulted from the driver trying to avoid
hitting the animal. Of those incidents in which the animal
was avoided, the crash most commonly involved an MV leav-
ing the roadway (29.0%); an MV hitting a tree, pole, or guard-
rail (21.4%); or an MV rollover (17.3%) (Table 2).
Reported by: JM Conn, MS, JL Annest, PhD, Office of Statistics and
Programming; A Dellinger, PhD, Div of Unintentional Injury
Prevention, National Center for Injury Prevention and Control, CDC.
Editorial Note: Nationally, nonfatal MV animal crash–
related injuries account for <1.0% of approximately three mil-
lion MV occupants treated in U.S. EDs annually (5). Direct
MV animal crashes represent nearly 4.0% of an estimated 6.1
million light-vehicle crashes reported to police in the United
States (1). However, in rural areas with large deer popula-
tions, MV animal crashes and associated occupant deaths and
injuries, wildlife loss, and property damage are important con-
cerns. For instance, in Wisconsin, MV deer crashes accounted
for nearly 16% of all statewide police-reported MV crashes in
2002 (6).
National estimates reported from this study are consistent
with state MV animal crash data reported to police. In this
study, the majority of MV occupant injuries resulted from
encounters between the MV and deer; however, 12% of those
injured resulted from MV crashes involving large domesti-
cated animals (e.g., horses and cattle). MV occupant injuries
can occur because of a direct MV collision with the large ani-
mal or from swerving or maneuvering to avoid a collision with
the animal. In this study, 63.8% of younger drivers swerved
to avoid the animal, resulting in an MV crash and subsequent
injury. Similar to other MV occupant injuries from crashes
that occur on U.S. highways, a majority of the injuries were
neck sprains/strains, and contusions/abrasions to the head and
face. One fourth of MV animal crash–related injuries were
treated in October and November at the height of the fall
deer hunting, mating, and migration season (7). MV animal
crashes are more likely to occur in the early morning hours
and especially at dusk, when deer are actively moving about





















All other MV crashes
FIGURE. Percentage of persons injured in motor-vehicle (MV)
large animal crashes, compared with persons injured in all
other MV crashes, by age group — United States, 2001–2002
TABLE 2. Estimated annual number and percentage of
persons treated in emergency departments for nonfatal motor-
vehicle (MV) large animal crash–related injuries, by selected
characteristics — United States, 2001–2002
Characteristic Estimated no. (%)* (95% CI†)
Diagnosis
Strain/Sprain  8,202 (36.5) (25.4–47.6)
Contusion/Abrasion  7,616 (33.9) (21.9–45.9)
Laceration  2,610 (11.6) (6.8–16.4)
Internal injury  1,204 (5.3) (3.1–7.5)
Other diagnosis§  2,867 (12.7) (7.9–17.5)
Primary body part affected
Neck  5,099 (22.7) (14.8–30.6)
Head/Face  6,333 (28.1) (18.1–38.1)
Upper trunk  3,442 (15.3) (9.2–21.4)
Lower trunk  2,718 (12.1) (7.9–16.3)
Upper extremity  2,307 (10.3) (6.0–14.6)
Lower extremity  1,226 (5.4) (2.8–8.0)
Multiple/All body parts  1,210 (5.4) (1.4–9.4)
Unknown     164¶ (0.7)¶ (—)
Month of treatment
January    946¶ (4.2)¶ (—)
February  1,367 (6.1) (3.8–8.4)
March  1,308 (5.8) (2.4–9.2)
April     936 (4.2) (2.0–6.4)
May  1,985 (8.8) (4.4–13.2)
June  1,935 (8.6) (4.8–12.4)
July  2,037 (9.1) (5.3–12.9)
August  1,590 (7.1) (4.5–9.7)
September  1,974 (8.8) (4.1–13.5)
October  2,780 (12.4) (7.8–17.0)
November  3,534 (15.7) (9.5–21.9)
December  2,107 (9.4) (4.6–14.2)
Type of animal involved
Deer 19,561 (86.9) (61.6–112.2)
Moose/Elk/Bear     187¶ (0.8)¶ (—)
Horse/Cow/Bull   2,750 (12.2) (6.1–18.3)
Circumstances
Directly hit animal 12,245 (54.4) (40.8–68.0)
Unknown     174¶ (0.8)¶ (—)
Swerved/slowed to avoid
collision with animal 10,080 (44.8) (29.5–60.1)
Hit tree/pole/guardrail  2,158 (21.4) (10.8–32.0)
Hit car/Hit by car     632¶ (6.3)¶ (—)
MV rollover  1,739 (17.3) (8.4–26.2)
Went off road  2,919 (29.0) (13.1–44.9)
Other type**     948 (9.4) (4.3–14.5)
Unknown  1,684 (16.7) (7.8–25.6)
Total 22,498 (100.0)
* Percentages might not total 100% because of rounding.
† Confidence interval.
§ Includes fracture, concussion, hematoma, dental, or other injury.
¶ Estimates might be unstable because they are based on <20 NEISS-
AIP cases or coefficient of variation is >30%.
** Includes fence, bridge, parked car, house, and other.
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The findings of this report are subject to at least three limi-
tations. First, although the risk for MV animal crash–related
injury can vary among states and local areas, NEISS-AIP is
designed to provide only national estimates and does not pro-
vide regional, state, or local estimates or estimates by urban
and rural categories. Second, because of the small number of
cases reported, this study excluded motorcyclists, who are
known to be at higher risk for injury in crashes (6). Finally,
NEISS-AIP only provides data on injured persons treated in
hospital EDs.
Prevention efforts have focused on warning signs to alert
drivers to animal crossings, speed restrictions, roadway fenc-
ing and underpasses/overpasses aimed at directing animals
toward safe passage, roadside clearing, roadside mirrors and
reflectors (i.e., to deflect headlight beams toward the sides of
the road to alert deer), and reduction of deer populations
through recreational hunting (7,9). Evaluation studies have
been conducted to assess the cost and effectiveness of these
methods, but the results are inconsistent (10). Interventions
with some supportive evidence (e.g., fences combined with
underpasses or overpasses) also are among the most
expensive to build and maintain.
Primary prevention of MV animal crashes can be accom-
plished by keeping large animals, especially deer, from enter-
ing the roadway or by providing drivers with more time to
react to a potentially dangerous situation. The same behaviors
that are recommended to help prevent crashes in general are
relevant for MV animal crashes. Driving within speed limits,
staying alert and reducing distracted and drowsy driving, and
eliminating alcohol-impaired driving will give drivers, par-
ticularly teenagers and younger adults, more time to react and
avoid collisions. Prevention of injury if a crash occurs can be
accomplished by the universal use of proper restraints, includ-
ing safety belts, child safety seats, and booster seats.
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Transmission of Hepatitis B Virus
in Correctional Facilities — Georgia,
January 1999–June 2002
Incarcerated persons have a disproportionate burden of
infectious diseases (1), including hepatitis B virus (HBV)
infection. Among U.S. adult prison inmates, the overall preva-
lence of current or previous HBV infection ranges from 13%
to 47%. The prevalence of chronic HBV infection among
inmates is approximately 1.0%–3.7%, two to six times the
prevalence among adults in the general U.S. population (1).
Incarcerated persons can acquire HBV infection in the com-
munity or in correctional settings (1). This report summa-
rizes the results of 1) an analysis of hepatitis B cases among
Georgia inmates reported to the Georgia Department of
Human Resources, Division of Public Health (DPH) during
January 1999–June 2002, including a retrospective investiga-
tion of cases reported during January 2001–June 2002; and 2)
a prevalence survey conducted in prison intake centers during
February–March 2003. These efforts identified cases of acute
hepatitis B in multiple Georgia prisons and documented evi-
dence of ongoing transmission of HBV in the state correc-
tional system. The findings underscore the need for hepatitis B
vaccination programs in correctional facilities.
The Georgia correctional system houses approximately
45,000 inmates in 68 correctional facilities; approximately
16,000 new inmates are admitted each year and processed
through one of five intake centers. The correctional system
does not routinely screen inmates for HBV infection, and
diagnostic testing is left to the judgment of individual physi-
cians. In August 2000, in response to two hepatitis B
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outbreaks at one Georgia correctional facility (2,3), DPH
began to monitor reports of acute hepatitis B cases among
inmates at all Georgia correctional facilities, as determined by
the inmates’ addresses on laboratory reports.
A case of acute HBV infection was defined as a positive
serologic test for IgM antibodies to hepatitis B core antigen
(IgM anti-HBc) on at least one occasion and at least one
additional supporting finding (e.g., compatible symptoms,
liver enzyme elevation, or another positive hepatitis B sero-
logic test), received by DPH during January 1999–June 2002.
Cases reported during January 2001–June 2002 were con-
firmed by retrospective review of the inmate’s medical and
laboratory records. The date of diagnosis of acute HBV infec-
tion was defined as the date that alanine aminotransferase
(ALT) or aspartate aminotransferase (AST) levels were elevated
at least two times greater than the upper limit of normal in
conjunction with a positive test for IgM anti-HBc. When ALT
or AST levels were not available, the date of the blood draw
with a positive IgM anti-HBc result was used as the approxi-
mate date of diagnosis.
Incarceration histories of inmates with acute HBV infec-
tions reported during January 2001–June 2002 were reviewed
to identify inmate locations and number of transfers between
correctional facilities before illness onset. Persons with asymp-
tomatic and symptomatic cases were considered to have been
infected while incarcerated if they were in prison or jail during
the 12 months or 6 months, respectively, before illness onset.
A prevalence survey to assess the HBV infection status of
prisoners on entry was conducted at three Georgia prison
intake centers for males and one intake center for females dur-
ing February–March 2003. Consenting inmates underwent
HBV serologic testing; all inmates at intake when the survey
was conducted were offered hepatitis B vaccine.
During January 1999–June 2002, a total of 92 cases of acute
HBV infection were identified, of which 57 (62%) were
reported during January 2001–June 2002 and included in the
retrospective investigation (Figure). Among the 57 inmates
with HBV infection, the median age was 34 years (range: 18–
59 years); 52 (91%) were male, and 35 (61%) were non-
Hispanic blacks. Ten (18%) had symptoms that included
jaundice, abdominal pain, fever, and vomiting. Seven (12%)
subsequently were determined to have chronic infections. The
chronic infection status of four inmates was not assessed.
Among the 57 inmates included in the retrospective inves-
tigation, the most frequently reported reason for HBV testing
was the presence of symptoms or elevated liver enzymes
(21 cases [37%]). Other reasons included reported character-
istics and behaviors that might be associated with HBV
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transmission (e.g., tattoos or unprotected sex contacts)
(14 [24%]), serologic testing performed as part of initial medi-
cal evaluation (13 [23%]), and being positive for human
immunodeficiency virus (five [9%]). Prison staff
reported counseling and providing medical follow-up for 52
(91%) of the 57 inmates.
The 57 cases were reported from 27 prisons and four pro-
bation detention centers in Georgia, with a mean of 1.8 cases
per facility and a range of one to three cases for the 30 facili-
ties that were not involved in the previously recognized out-
breaks (2,3). The 57 inmates had been incarcerated for a
median of 2.2 years (range: 0–23.7 years) before illness onset
and had been transferred 1.4 times on average (median: one
time; range: one to seven times) during the 12 months before
diagnosis. The majority of HBV infections (41 [72%]) were
acquired in prison. Of the remaining 16 cases, 13 (81%)
occurred in persons who had been in prison or jail for 1–6
months before receiving a diagnosis. The remaining three
(19%) inmates were asymptomatic and had been in prison or
jail for 10–11 months before receiving a diagnosis.
As of August 2002, the seven inmates who had chronic
infections had been transferred among prison facilities 13 times
during the cumulative 89 months of incarceration that fol-
lowed their diagnosis, resulting in a mean of 1.8 transfers per
person-year of incarceration (median: two transfers; range: zero
to five transfers). Three inmates with chronic infection were
released from prison.
Of 546 inmates surveyed at intake during February–March
2003, a total of 489 (90%) consented to serologic testing,
and 428 (78%) consented to hepatitis B vaccination. Of the
489 inmates tested, three (0.6%) had acute HBV infections,
four (0.8%) had chronic infections, 64 (13%) had evidence
of resolved infections, and 374 (76%) were susceptible to HBV
infection. Two of three inmates with acute infection had spent
5.5–11.0 months in jail before intake.
Reported by: K Arnold, MD, Georgia Dept of Human Resources, Div
of Public Health; M LaMarre, MN, J Taussig, MPH, Georgia Dept of
Corrections. BP Bell, MD, L Farrington, MS, Div of Viral Hepatitis,
National Center for Infectious Diseases; S Vong, MD, PR Patel, MD,
EIS officers, CDC.
Editorial Note: HBV is a bloodborne pathogen, transmitted
by percutaneous or permucosal exposure to infectious blood
or body fluids. The prevalence of chronic infection is higher
among prison inmates (1.0%–3.7%) than among the general
U.S. population (0.5%) (1), reflecting an overrepresentation
of persons entering prison who are at high risk for HBV
infection (e.g., injection-drug users and those with reported
histories of multiple sex partners). The prevalence of chronic
infection among the intake population in this report (0.8%)
suggests that high-risk behaviors practiced within the
community before incarceration might not account entirely
for the burden of HBV infection in correctional facilities.
Although studies are limited, transmission of HBV infection
within correctional settings has been documented, with inci-
dence ranging from 0.8% to 3.8% per year (2,4–6).
The retrospective investigation described in this report iden-
tified an increase in HBV infections in Georgia correctional
facilities, beginning in January 2001. This increase likely was
related to multiple factors, including enhanced surveillance
and increased diagnostic testing by correctional medical staff.
Changes in diagnostic practices might have occurred because
of increased awareness of hepatitis B among medical staff
after outbreaks at a Georgia correctional facility in June 2000
and again in June 2001. Nonetheless, the number of reported
cases probably underestimates the extent of HBV transmis-
sion in the correctional system because the majority of per-
sons with acute HBV infection are asymptomatic and
investigations of single cases are not conducted routinely. In
the first previous outbreak, one symptomatic patient reported
to DPH was associated with a cluster of 11 acute cases, and
four chronic HBV infections were identified (2).
The majority of inmates with identified acute HBV infec-
tions were housed in multiple Georgia correctional facilities
and were infected during their incarceration, suggesting wide-
spread ongoing transmission in multiple facilities. Inmates
infected with HBV were transferred frequently among facili-
ties. Thus, potential sources of HBV transmission were
distributed throughout the prison system.
In the Georgia correctional system, approximately one third
of inmates are released each year (7). Inmates who become
chronically infected and subsequently are released represent
potential sources of infection for others in the community. In
addition, susceptible inmates who are released continue to be
at increased risk for HBV infection (1). The majority of
inmates in the intake survey were susceptible to HBV infection
FIGURE. Number* of cases of acute hepatitis B reported in
correctional facilities, by month and year — Georgia, January
1999–June 2002
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and consented to vaccination, suggesting that vaccination
efforts in correctional facilities might effectively capture
susceptible, high-risk populations.
Although data are lacking regarding the overall burden of
HBV infection in correctional systems, the ongoing transmis-
sion demonstrated in Georgia prisons might be occurring in
other states, where similar conditions are likely to exist. All
inmates who receive a medical evaluation should be vacci-
nated to prevent HBV infection (1). However, the majority
of state correctional systems in the United States, including
the Georgia system, do not have hepatitis B vaccination pro-
grams (1). Implementation of such programs in correctional
settings nationwide could result in a considerable reduction
in the hepatitis B–associated disease burden, not only by elimi-
nating transmission among the incarcerated population, but
also by reducing transmission in the community (8).
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Hepatitis B Vaccination of Inmates
in Correctional Facilities —
Texas, 2000–2002
In December 2002, approximately 2.2 million persons were
incarcerated in the United States (1); an estimated 8 million
were released to the community that year (2). In 2001,
approximately 22,000 acute hepatitis B cases and 78,000 new
hepatitis B virus (HBV) infections occurred in the United
States (3); an estimated 29% of these cases were in persons
who had been incarcerated previously (4). The majority of
HBV infections among incarcerated persons are acquired in
the community; however, infection also is transmitted within
correctional settings (2). Hepatitis B vaccination of incarcer-
ated persons is recommended to prevent transmission in cor-
rectional facilities and in previously incarcerated persons on
their return to the community (2). In May 2000, the Texas
Department of Criminal Justice (TDCJ), which oversees cus-
tody of state jail and prison inmates, implemented a hepatitis
B vaccination program. To determine hepatitis B vaccination
rates of inmates during 2000–2002, TDCJ reviewed charts of
inmates released during a 3-day period for documentation of
vaccination. This report summarizes the results of that study,
which indicated that rates of vaccine acceptance and vaccine
series completion among inmates were high. Establishing hepa-
titis B vaccination programs in prisons and jails can prevent a
substantial proportion of HBV infections among adults in
the outside community.
During 2000–2002, TDCJ housed approximately 151,000
inmates in 105 adult facilities, including prisons (median sen-
tence of inmates: 9 years; range: 2–99 years) and jails (median
sentence of inmates: 1.3 years; range: 3 months–2 years).
Approximately 40,000 new offenders enter these facilities
annually, and an estimated 1% of inmates are transferred be-
tween facilities daily (5,6). In 1999, state funds were appropri-
ated for hepatitis B vaccination of all inmates in jails and prisons.
Before implementation of the vaccination program, a cost-
effectiveness model was developed that estimated the cost
effectiveness of prevaccination testing for immunity to HBV
infection among inmates. Stored serum specimens from 889
inmates incarcerated during 1998–1999 were tested for anti-
bodies to hepatitis B core antigen (anti-HBc); HBV preva-
lence was 18%. The model estimated that at a threshold
prevalence of 25%, the cost of a program with prevaccination
testing was equivalent to that of vaccination without testing;
at lower prevalence, prevaccination testing would not be cost
effective (Figure). On the basis of these findings, all of the
estimated 40,000 entering inmates were offered vaccine with-
out prevaccination testing.
Entering inmates were offered the first hepatitis B vaccine
dose at the time of admission. Persons who were already
incarcerated were offered the first dose at the time of their
annual health evaluation, which occurred on their anniver-
sary month of incarceration. After vaccination of incarcerated
persons, only newly admitted inmates were offered vaccine.
Vaccine was administered on a 0-, 2-, and 4-month sched-
ule. An electronic pharmacy auto-renewal system was used to
send second and third vaccine doses to the appropriate facil-
ity for each inmate. Health-care workers also recorded vac-
cine dose administration in each inmate’s medical record,
enabling inmates to complete the vaccination series despite
frequent transfers within the system.
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In February 2002, TDCJ evaluated vaccine acceptance and
series completion rates. Charts of 232 prison inmates and 211
jail inmates released during a 3-day period were audited for
receipt of hepatitis B vaccine; 426 (96%) inmates with no
record of previous vaccination or HBV infection were consid-
ered to be eligible for vaccination. Lack of documentation of
a vaccination encounter was interpreted as a failure to offer
vaccine, and only a signed informed refusal form was counted
as a vaccination refusal.
Hepatitis B vaccine was offered to 319 (75%) of 426
inmates. Prison inmates were more likely to be offered vac-
cine (185/220 [84%]) than jail inmates (134/206 [65%])
(p<0.001), which might be related to higher inmate turnover
and lack of staff contact time in jails (Table). However, accep-
tance of the first vaccine dose was higher among jail inmates
(114/134 [85%]) than among prison inmates (134/185
[72%]) (p = 0.005).
Among 125 prison and 99 jail inmates who began vaccina-
tion and were incarcerated for >4 months, the 3-dose comple-
tion rate was 96% and 54%, respectively. In December 2002,
the hepatitis B vaccination program was suspended because
of a lack of funds.
Reported by: M Kelley, MD, L Linthicum, MD, Texas Dept of
Criminal Justice. A Spaulding, MD, K Billah, PhD, C Weinbaum,
MD, Div of Viral Hepatitis, National Center for Infectious Diseases;
R Small, Div of STD Prevention, National Center for HIV, STD, and
TB Prevention, CDC.
Editorial Note: Evaluation of the TDCJ hepatitis B vaccina-
tion program demonstrated that high vaccine coverage could
be achieved for inmates in a state correctional system. Incar-
ceration provides an opportunity to vaccinate persons at high
risk typically not served by prevention services in the public
or private sectors, and vaccination of incarcerated populations
is cost effective (7).
The findings in this report illustrate the need to tailor a
program to a particular facility. Completion of the vaccine
series is a more feasible goal for long-term facilities; short-
term facilities should initiate the vaccine series, supply an
immunization record and, where feasible, provide informa-
tion at discharge about facilities offering the remaining vac-
cine doses. Vaccination also can be completed if the person
returns to a correctional institution.
Prevaccination testing to detect existing immunity can elimi-
nate the cost of revaccinating persons who were vaccinated
previously or infected. TDCJ’s decision not to perform
prevaccination testing was based on a model that included
the costs of testing and vaccination and the series completion
rate. The model assumed that all inmates who received the
first vaccine dose would return for subsequent doses; if attri-
tion caused by release was included in the model,
prevaccination testing would only be cost effective if the preva-
lence of immunity was higher. Changes in prevalence of
immunity to HBV infection or costs (e.g., vaccine, labor, and
testing) also would change the cost effectiveness of
prevaccination testing. In particular, immunity to HBV
infection in young adults is changing rapidly within most com-
munities because of an increase in vaccinated adolescents. If
adequate immunization records are not available for inmates,
periodic monitoring of the prevalence of immunity to HBV
infection using a serologic marker to detect both infection
(i.e., anti-HBc) and immunization (i.e., antibodies to
hepatitis B surface antigen) will help corrections officials
determine when prevaccination testing might reduce costs (2).
FIGURE. Cost effectiveness of prevaccination testing for
immunity to hepatitis B virus (HBV) infection among jail and
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At threshold prevalence (25%), cost of
prevaccination testing was equivalent
to vaccination without testing
Source: Texas Department of Criminal Justice.
TABLE. Number and percentage of eligible inmates* in jails
and prisons who were offered hepatitis B vaccine, by  type of
facility and vaccine outcome — Texas, 2000–2002†
Jails Prisons
(N = 206) (N = 220)
Vaccine outcome No. (%) No. (%)
Offered vaccine 134 (65) 185 (84)§
Accepted at least 1 dose 114 (85)§ 134 (72)
Accepted at least 2 doses 87 (65) 127 (69)
Accepted all 3 doses 53 (40) 120 (65)
Completed series/total receiving first
dose and incarcerated >4 months 53/99 (54) 120/125 (96)§
Source: Texas Department of Criminal Justice.
* Eligible inmates were those who did not have a record of previous vacci-
nation or hepatitis B virus infection.
†
Data for sample abstracted from medical records of all prison and jail
inmates released during a 3-day period in February 2002.
§
p<0.05, Fisher’s exact test.
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 The findings in this report are subject to at least two limi-
tations. First, inmates with shorter sentences are more likely
to be discharged and might be overrepresented by the sam-
pling. Because inmates with short sentences might not have
been incarcerated long enough to complete the vaccination
series, more inmates might have completed the vaccination
series than this study demonstrated. Second, lack of long-term
follow-up precludes evaluation of the eventual series comple-
tion by jail inmates, who might have accessed additional doses
outside the correctional system or during subsequent incar-
cerations.
Hepatitis B vaccination of inmates in state correctional
facilities is feasible if resources are available to purchase and
administer vaccine. In 2000, a survey of state correctional
facility medical directors indicated that the majority of prison
systems would vaccinate inmates if resources were available
(8). Although hepatitis B vaccination of inmates has been rec-
ommended since the vaccine first became available in 1982
(9), only five states (Hawaii, Michigan, New Mexico, Ver-
mont, and Wisconsin) vaccinate inmates routinely (D. Burnett,
M.D., Wisconsin Department of Corrections and F. Pullara,
M.D., New Mexico Department of Corrections, personal com-
munications, 2004) (8). Collaborations between public health
and corrections authorities at the state and local level are
essential to overcome barriers to vaccination program imple-
mentation.
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Tuberculosis Associated with
Blocking Agents Against Tumor
Necrosis Factor-Alpha —
California, 2002–2003
The Food and Drug Administration (FDA) has determined
that tuberculosis (TB) disease is a potential adverse reaction
from treatment with the tumor necrosis factor-alpha (TNF-α)
antagonists infliximab (Remicade®), etanercept (Enbrel®), and
adalimumab (Humira®)*; the three products are labeled
accordingly (1,2). These products work by blocking TNF-α,
an inflammatory cytokine, and are approved for treating rheu-
matoid arthritis and other selected autoimmune diseases.
TNF-α is associated with the immunology and pathophysi-
ology of certain infectious diseases, notably TB; blocking
TNF-α can allow TB disease to emerge from latent Mycobac-
terium tuberculosis infection. In 2002, a California county
health department reported three cases of TB disease occur-
ring in association with infliximab therapy. This report sum-
marizes those cases and nine subsequently reported cases and
provides interim recommendations for TB prevention and
management in recipients of these blocking agents. Health-
care providers should take steps to prevent TB in
immunocompromised patients and remain vigilant for TB as
a cause of unexplained febrile illness.
Case Reports
Case 1. In January 2002, a U.S.-born man aged 55 years
with rheumatoid arthritis had pulmonary TB disease diag-
nosed 17 months after starting infliximab therapy. In 1995,
he had a positive tuberculin skin test (TST) and reportedly
took isoniazid for 12 months; however, his adherence to
therapy was questionable. During September 2000–January
2002, he received 13 infusions of infliximab, and his arthritic
symptoms decreased. However, in January he had fever and
weight loss. Four weeks later, a supraclavicular lymph node
became enlarged, and a chest radiograph revealed a right-
upper-lobe lung cavity with a nodular infiltrate. M. tuberculo-
sis was isolated from sputum and lymph node specimens, and
his condition improved with anti-TB medications. In July
2002, he again lost weight. He had smoked cigarettes for many
years and was found to have lung cancer; he died in Novem-
ber 2002.
Case 2. A woman aged 64 years with rheumatoid arthritis
had pulmonary and pericardial TB disease diagnosed in June
2002. She had begun infliximab therapy in September 2001
* Respectively, Centocor, Malvern, Pennsylvania; Immunex Corporation,
Thousand Oaks, California; and Abbott Laboratories, Abbott Park, Illinois.
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and received 7 doses before onset of fever and weight loss in
April 2002. Her chest radiograph revealed a large pericardial
effusion and a right-upper-lobe lung infiltrate. M. tuberculosis
resistant to isoniazid, rifampin, pyrazinamide, and ethambu-
tol was isolated from sputum and pericardial fluid. The
patient was born in the Philippines, where TB often is drug
resistant (3). In 1999, she was exposed to a person with drug-
susceptible TB in the United States and subsequently had two
TSTs with negative results in 2000; however, she was taking
prednisone for her arthritis at the time of the TSTs. After 12
months of therapy with second-line anti-TB medications, her
medical condition has improved.
Case 3. A U.S.-born woman aged 54 years was exposed to
contagious TB in 1996; she had a positive TST result during
the contact investigation but was not treated for latent TB
infection (LTBI). The patient has Crohn’s disease and received
infliximab in February 2001 and June 2002. Two weeks after
her second infusion, but 16 months after her first infusion,
she sought care for cough, fever, and abdominal pain. Her
chest radiograph revealed upper-lobe lung nodules with a pleu-
ral effusion, and sputum specimens yielded M. tuberculosis.
She started standard, four-drug anti-TB therapy but experi-
enced gastrointestinal intolerance. Isoniazid was discontinued,
and she was free of TB disease after treatment with rifampin,
pyrazinamide, and ethambutol.
Additional Reports
In 2003, the state of California Department of Health
Services asked local jurisdictions to report TB cases associated
with TNF-α antagonists since January 2002. As of Septem-
ber 2003, nine additional reports had been received, for a
TABLE. Characteristics of 12 cases of reported tuberculosis (TB) disease in patients receiving tumor necrosis factor-alpha (TNF-α)
antagonist therapy — California, January 2002–August 2003
TB testing
Patient Other before TNF-α Other
age Reason for TNF-α Site of TB Foreign TB risk antagonist immunosuppressing
(yrs) antagonist therapy disease born* factors† therapy§ medication¶
55 Rheumatoid arthritis Lung, supraclavicular node No Yes Yes None
64 Rheumatoid arthritis Lung, pericardium Yes Yes Yes Prednisone
54 Crohn’s disease Lung No Yes Yes Prednisone
64 Rheumatoid arthritis Disseminated Yes No No None
72 Rheumatoid arthritis Disseminated Yes Yes Yes Prednisone, methotrexate
41 Psoriatic arthritis Kidneys Yes Yes Unknown None
70 Dermatomyositis Lung No Yes No Prednisone, azathioprine
23 Crohn’s disease Intestines Yes No No None
52 Rheumatoid arthritis Mediastinum, lung Yes Yes No Methotrexate
29 Juvenile rheumatoid arthritis Lung Yes No No Prednisone
73 Rheumatoid arthritis Lung Yes No No Prednisone, methotrexate
44 Crohn’s disease Pleura No No Yes Prednisone
* Persons from countries where TB is prevalent are at increased risk for latent TB infection (LTBI).
†
History of latent TB infection (LTBI) or known contact with person with TB disease.
§
Tuberculin skin test or chest radiography if history of LTBI.
¶
At time of TB disease diagnosis.
total of 12 cases diagnosed during January 2002–August 2003
(Table). The median patient age was 54.5 years (range: 23 to
73 years), and eight (67%) of the patients were female. Eleven
of the patients had TB disease after receiving infliximab. One
patient had TB disease while receiving chronic etanercept
therapy.
Eleven of the patients had at least one risk factor for LTBI
(e.g., born in countries where TB is prevalent or contact with
a person with TB disease). Eight were taking other immuno-
suppressive therapies at the time of their TB diagnoses. Three
patients underwent a medical history for TB risk factors
before beginning therapy with a TNF-α antagonist. In addi-
tion to the patient in case 1, a second patient died (from car-
diomyopathy) while being treated for TB disease.
Reported by: P Costamagna, K Furst, MD, K Tully, San Joaquin
County Public Health Svcs; J Landis, Santa Cruz County Health Svcs;
K Moser, MD, San Diego County Dept of Health; L Quach, J Kwak,
County of Orange Health Care Agency; H Calvet, MD, B Lindsey, Long
Beach City Dept of Health and Human Svcs; J Flood, MD, California
Dept of Health Svcs. M Braun, MD, Center for Biologics Evaluation
and Research; J Siegel, MD, Center for Drug Evaluation and Research,
Food and Drug Administration. K Winthrop, MD, J Jereb, MD,
Z Taylor, MD, M Iademarco, MD, K Castro, MD, Div of TB
Elimination, National Center for HIV, STD, and TB Prevention, CDC.
Editorial Note: As of January 2004, FDA’s adverse-event
reporting system had received several hundred reports, mostly
from outside the United States, of TB disease in patients who
received TNF-α  antagonists. Manufacturers of these
products are required to report known cases, but reporting is
voluntary for others. The majority of the cases probably rep-
resent progression of LTBI to TB disease, although the con-
tribution of newly acquired M. tuberculosis infection to the
Vol. 53 / No. 30 MMWR 685
total number of reports is unknown (1). Reports have included
atypical presentations, extrapulmonary and disseminated
disease, and deaths (1,4,5).
In California, after the initial three reports, nine additional
cases of TB disease were reported during January 2002–
August 2003 in patients taking TNF-α antagonists. Although
reporting of TB cases is mandatory in California, reporting
the association with TNF-α antagonists was voluntary, and
an underestimate might have resulted.
Eight of the 12 patients in California were born in coun-
tries where TB is prevalent. In certain instances, physicians
had not screened for risk factors for M. tuberculosis infection
or tested their patients for infection before beginning therapy
with TNF-α antagonists. In other instances, testing was per-
formed, but LTBI was not diagnosed, possibly because of
cutaneous anergy. Many patients who receive TNF-α antago-
nists already are receiving other immunosuppressive therapies,
and certain conditions such as rheumatoid arthritis also can
decrease sensitivity to tuberculin; therefore, TST results at the
time of initiating TNF-α antagonist therapy might be falsely
negative. Some experts advocate treating for presumed LTBI
when a candidate for TNF-α antagonists has risk factors for
M. tuberculosis infection but a negative TST result (4,5).
TNF-α, an inflammatory cytokine expressed by activated
macrophages, T-cells, and other immune cells, plays a crucial
role in the host response against M. tuberculosis and other
intracellular pathogens. Infliximab and adalimumab are mono-
clonal antibodies; etanercept is a dimeric soluble form of the
TNF-α receptor. All three products are approved for the treat-
ment of patients with rheumatoid arthritis. Infliximab also is
approved for Crohn’s disease, and etanercept is approved for
specific other arthritides and for psoriasis. Use of these agents
has been associated with other life-threatening infectious dis-
eases besides TB, including candidiasis, histoplasmosis,
aspergillosis, and listeriosis (1). TNF-α antagonists often are
used in conjunction with other immunosuppressive therapies,
particularly glucocorticoids and methotrexate. Whether the
increased rates of TB or other infectious diseases are caused
by interactions among these therapies is unknown.
Diagnosing LTBI in candidates for TNF-α  antagonist
therapy is challenging (Box). For patients who undergo treat-
ment for LTBI, the optimal time for starting TNF-α antago-
nist therapy is undetermined. Some experts advocate
postponing therapy until LTBI treatment is complete. How-
ever, this delay might be impractical (4,6). The risk for TB
relapse in patients previously cured of TB disease and subse-
quently treated with TNF-α antagonists is unknown.
BOX. Recommendations for screening, diagnosis, and
treatment of latent TB infection (LTBI) and tuberculosis (TB)
in patients administered or scheduled to receive tumor
necrosis factor-alpha (TNF-α) antagonists
• Screen patients for risk factors for Mycobacterium tuber-
culosis and test them for infection before initiating
immunosuppressive therapies, including TNF-α
antagonists. Risk factors include birth in a country where
TB is prevalent or history of any of the following:
residence in a congregate setting (e.g., jail or prison,
homeless shelter, or chronic-care facility), a positive
tuberculin skin test (TST) result, substance abuse (i.e.,
injection or noninjection), health-care employment in
settings with TB patients, and chest radiographic find-
ings consistent with previous TB (1).
• Diagnosis and treatment of LTBI and TB disease should
be in accordance with published guidelines (1–3).
• In patients who are immunocompromised (e.g., because
of therapy or other medical conditions), interpret a TST
induration of >5 mm as a positive result and evidence
of M. tuberculosis infection.
• Interpret a TST induration of <5 mm as a negative
result but not an exclusion for M. tuberculosis infection.
Results from control-antigen skin testing (e.g., Candida)
do not alter the interpretation of a negative TST result.
• Test to exclude TB disease before starting treatment for
LTBI (1,2).
• Start treatment for LTBI before commencing TNF-α
blocking agents, preferably with 9 months of daily
isoniazid (1,2).
• Consider treating for LTBI in patients who have nega-
tive TST results but whose epidemiologic and clinical
circumstances suggest a probability of LTBI.
• Pursue TB disease as a potential cause of febrile or
respiratory illness in immunocompromised patients,
including those receiving TNF-α blocking agents.
• Consider postponing TNF-α antagonist therapy until
the conclusion of treatment for LTBI or TB disease.
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TABLE. Number of human cases of West Nile virus (WNV) illness,
by state — United States, 2004*
West Other Total
Neuroinvasive Nile clinical/ reported
State disease† fever§ unspecified¶ to CDC** Deaths
Alabama 2 0 0 2 0
Arizona 99 26 122 247 2
Arkansas 1 2 0 3 0
California 28 31 10 69 2
Colorado 9 35 0 44 0
Florida 4 3 0 7 0
Illinois 0 1 1 2 0
Iowa 1 2 0 3 1
Michigan 1 0 0 1 0
Missouri 1 0 0 1 0
Nebraska 0 1 0 1 0
Nevada 2 0 0 2 0
New Mexico 1 4 0 5 0
New York 2 1 0 3 0
North Dakota 0 1 0 1 0
Ohio 1 0 0 1 1
Pennsylvania 1 0 0 1 0
South Dakota 1 8 0 9 0
Texas 2 1 0 3 1
Wyoming 0 1 0 1 0
Total 156 117 133 406 7
* As of August 3, 2004.
† Cases with neurologic manifestations (i.e., West Nile meningitis, West
Nile encephalitis, and West Nile myelitis).
§ Cases with no evidence of neuroinvasion.
¶ Illnesses for which sufficient clinical information was not provided.
** Total number of human cases of WNV illness reported to ArboNet by
state and local health departments.
If active TB disease develops during TNF-α antagonist
therapy, the TNF-α antagonist should be discontinued, at least
until the anti-TB regimen has been started and the patient’s
condition has improved. The optimal time for resuming
TNF-α antagonist therapy is undetermined. Outcomes with
other immunosuppressive agents during the treatment of TB
disease have been variable. Use of glucocorticosteroids during
the treatment of TB disease is considered safe (7), and studies
of TB disease in organ transplant recipients suggest that sur-
vival is not decreased by the use of cyclosporine or azathio-
prine (8). Etanercept, administered in a phase-1 clinical trial
along with a standard initial anti-TB regimen, did not delay
the resolution of TB disease markers in a group of patients
coinfected with human immunodeficiency virus in compari-
son with historical controls; adverse effects were not
detected (9). However, use of anti–T-cell agents in transplant
recipients with TB disease is associated with increased mor-
tality; whether this increased mortality is because of the sup-
pression of immune response or the dysfunction of the
transplanted organ is unclear (8).
Practitioners who prescribe TNF-α antagonists should edu-
cate their patients about the symptoms of TB disease, with
added emphasis on extrapulmonary symptoms, which can
include fever, malaise, or development of a mass. A patient
with symptoms should undergo diagnostic testing for TB. In
addition to following local reporting requirements, health-
care providers should report TB cases associated with TNF-α
antagonists to FDA’s Medwatch system (available at http://
www.fda.gov/medwatch).
Ongoing clinical trials are using both approved and experi-
mental TNF-α antagonists in the treatment of additional con-
ditions (4). Novel therapies that inhibit other related
inflammatory cytokines are under development. As the use of
these blocking agents expands, associated cases of TB might
increase. Vigilance for TB in association with these agents is
critical to early recognition and successful treatment.
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West Nile Virus Activity — United
States, July 28–August 3, 2004
During July 28–August 3, a total of 141 cases of human
West Nile virus (WNV) illness were reported from 11 states
(Alabama, Arizona, California, Colorado, Florida, Illinois,
Nevada, New York, North Dakota, South Dakota, and Texas).
During 2004, a total of 20 states have reported a total of 406
cases of human WNV illness to CDC through ArboNET
(Table, Figure). Of these, 247 (61%) were reported from
Arizona. A total of 226 (57%) of the 406 cases occurred in
males; the median age of patients was 51 years (range:
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1 month–99 years). Illness onset ranged from April 20 to July
29; seven cases were fatal.
A total of 38 presumptive West Nile viremic blood donors
(PVDs) have been reported to ArboNET in 2004. Of these,
31 (82%) were reported from Arizona, two each from Cali-
fornia and South Dakota, and one each from Colorado, Iowa,
and New Mexico. Of the 38 PVDs, two persons aged 66 and
69 years subsequently had neuroinvasive illness, and seven
persons (median age: 55 years [range: 22–72 years]) subse-
quently had West Nile fever.
 In addition, during 2004, a total of 1,823 dead corvids
and 223 other dead birds with WNV infection have been
reported from 34 states. WNV infections in horses have been
reported from 20 states (Alabama, Arizona, California, Colo-
rado, Florida, Idaho, Iowa, Kentucky, Minnesota, Mississippi,
Missouri, Nevada, North Carolina, Ohio, Oklahoma, South
Dakota, Tennessee, Texas, Virginia, and Wyoming) and in a
dog from New Mexico. WNV seroconversions have been
reported in 253 sentinel chicken flocks from seven states
(Arizona, California, Delaware, Florida, Louisiana, Nebraska,
FIGURE. Areas reporting West Nile virus (WNV) activity —
United States, 2004*
* As of 3 a.m., Mountain Standard Time, August 3, 2004.
Human WNV illness
Nonhuman WNV infection only
and Nevada) and in two wild hatchling birds from Ohio. Three
seropositive sentinel horses were reported from Puerto Rico.
A total of 1,486 WNV-positive mosquito pools have been
reported from 24 states (Arizona, Arkansas, California, Colo-
rado, Connecticut, Georgia, Illinois, Indiana, Kansas, Louisi-
ana, Michigan, Mississippi, Missouri, Nebraska, Nevada, New
Jersey, New Mexico, Ohio, Pennsylvania, South Dakota,
Tennessee, Texas, Utah, and Virginia).
Additional information about national WNV activity is
available from CDC at http://www.cdc.gov/ncidod/dvbid/
westnile/index.htm and at http://westnilemaps.usgs.gov.
Notice to Readers
Final 2003 Reports of Notifiable Diseases
The notifiable diseases tables on pages 688–696 summarize
final National Notifiable Diseases Surveillance System data
for 2003. Final as of June 30, 2004, these data will be pub-
lished in more detail in the Summary of Notifiable Diseases,
United States, 2003 (1). Because no cases of anthrax, Powassan
encephalitis, western equine encephalitis, paralytic poliomy-
elitis, or yellow fever were reported in the United States dur-
ing 2003, these nationally notifiable diseases do not appear in
these tables. Policies for reporting notifiable disease cases can
vary by disease or reporting jurisdiction depending on case
status classification (i.e., confirmed, probable, or suspected).
Population estimates for the states and for Puerto Rico are
from the U.S. Census Bureau as of July 1, 2002 (2). Popula-
tion numbers for territories are 2002 estimates from the U.S.
Census Bureau IDB Data Access—Display Mode (3).
References
1. CDC. Summary of notifiable diseases, United States, 2003. MMWR
2003;52(54) (in press).
2. U.S. Census Bureau Population Division. Annual estimates of the popu-
lation for the United States and states, and for Puerto Rico: April 1,
2000 to July 1, 2003. Available at http://eire.census.gov/popest/data/
states/tables/NST-EST2003-01.xls.
3. U.S. Census Bureau. IDB Data Access—Display Mode. Available at
http://www.census.gov/ipc/www/idbprint.html.
688 MMWR August 6, 2004
TABLE 2. Reported cases of notifiable diseases,* by geographic division and area — United States, 2003
Total resident
population Botulism
Area (in thousands) AIDS† Foodborne Infant Other§ Brucellosis Chancroid¶
UNITED STATES 287,974 44,232** 20 76 33 104 54
NEW ENGLAND 14,134 1,697 1 1 - - 3
Maine 1,295 52 - - - - -
N.H. 1,274 37 1 - - - -
Vt. 616 16 - - - - -
Mass. 6,422 757 - - - - 3
R.I. 1,068 102 - - - - -
Conn. 3,459 733 - 1 - - -
MID. ATLANTIC 40,038 10,142 1 23 1 9 11
Upstate N.Y. 11,385 1,589 - 2 - 1 1
N.Y. City 7,749 5,133 - 1 1 3 9
N.J. 8,575 1,514 - 3 - 1 -
Pa. 12,329 1,906 1 17 - 4 1
E.N. CENTRAL 45,635 3,875 - 3 - 9 -
Ohio 11,409 775 - 2 - 1 -
Ind. 6,157 506 - 1 - - -
Ill. 12,586 1,734 - - - - -
Mich. 10,043 676 - - - 5 -
Wis. 5,440 184 - - - 3 -
W.N. CENTRAL 19,464 844 - - 1 4 -
Minn. 5,025 179 - - - 2 -
Iowa 2,936 75 - - - - -
Mo. 5,670 404 - - - - -
N. Dak. 634 2 - - - - -
S. Dak. 760 13 - - 1 1 -
Nebr. 1,728 60 - - - 1 -
Kans. 2,712 111 - - - - -
S. ATLANTIC 53,564 12,191 - 5 - 13 29
Del. 806 216 - 3 - - -
Md. 5,451 1,572 - 1 - - 1
D.C. 569 961 - - - - -
Va. 7,288 786 - - - 2 -
W. Va. 1,805 95 - - - - -
N.C. 8,306 1,102 - - - 1 2
S.C. 4,104 778 - - - - 24
Ga. 8,544 1,907 - 1 - - -
Fla. 16,692 4,774 - - - 10 2
E.S. CENTRAL 17,225 2,035 - 1 - 4 1
Ky. 4,090 220 - - - - 1
Tenn. 5,790 835 - 1 - - -
Ala. 4,479 471 - - - 1 -
Miss. 2,867 509 - - - 3 -
W.S. CENTRAL 32,409 4,864 - 1 3 34 3
Ark. 2,706 189 - - - 1 -
La. 4,476 1,048 - - - 1 -
Okla. 3,490 214 - - - - -
Tex. 21,737 3,413 - 1 3 32 3
MOUNTAIN 19,033 1,501 2 9 1 8 5
Mont. 910 7 - - - - -
Idaho 1,343 25 - - - - -
Wyo. 499 8 - - - 1 1
Colo. 4,501 368 1 2 1 1 -
N. Mex. 1,852 111 - - - 3 -
Ariz. 5,441 628 - - - 1 2
Utah 2,319 75 1 5 - 2 2
Nev. 2,167 279 - 2 - - -
PACIFIC 46,472 6,863 16 33 27 23 2
Wash. 6,067 527 11 - - 1 -
Oreg. 3,520 242 - 3 1 - 2
Calif. 35,002 5,967 2 29 26 19 -
Alaska 641 17 3 - - 1 -
Hawaii 1,241 110 - 1 - 2 -
Guam 161 7 - - - - 7
P.R. 3,859 1,065 - - - - -
V.I. 108 34 - - - - -
Amer. Samoa 57 1 - - - - -
C.N.M.I. 74 2 1 - - - -
N: Not Available. U: Unavailable. -: No reported cases.
* No cases of anthrax were reported in 2003.
† Total number of acquired immunodeficiency syndrome (AIDS) cases reported to the Division of HIV/AIDS Prevention—Surveillance and Epidemiology, National Center for HIV,
STD, and TB Prevention (NCHSTP), through December 31, 2003.
§ Includes cases reported as wound and unspecified botulism.
¶ Totals reported to the Division of Sexually Transmitted Diseases Prevention, NCHSTP, as of May 1, 2004.
** Total includes 220 cases in persons with unknown state of residence.
Vol. 53 / No. 30 MMWR 689
TABLE 2. (Continued) Reported cases of notifiable diseases, by geographic division and area — United States, 2003
Area Chlamydia* Cholera Coccidioidomycosis Cryptosporidiosis Cyclosporiasis Diphtheria
UNITED STATES 877,478 2 4,870 3,506 75 1
NEW ENGLAND 28,400 - 1 193 10 -
Maine 2,030 - N 20 - -
N.H. 1,616 - - 26 - -
Vt. 1,060 - - 32 N -
Mass. 11,301 - - 78 6 -
R.I. 3,000 - 1 17 - -
Conn. 9,393 - N 20 4 -
MID. ATLANTIC 110,682 - - 452 27 1
Upstate N.Y. 21,853 - N 140 3 -
N.Y. City 35,369 - - 126 9 -
N.J. 16,169 - - 19 9 -
Pa. 37,291 - N 167 6 1
E.N. CENTRAL 158,405 - 7 1,039 2 -
Ohio 42,522 - - 173 - -
Ind. 17,075 - N 126 - -
Ill. 48,294 - - 102 - -
Mich. 32,572 - 7 152 2 -
Wis. 17,942 - - 486 - -
W.N. CENTRAL 52,026 - 4 600 - -
Minn. 10,714 - N 155 - -
Iowa 6,491 - N 122 - -
Mo. 18,570 - 1 52 - -
N. Dak. 1,655 - N 15 N -
S. Dak. 2,608 - - 49 - -
Nebr. 4,739 - 3 33 - -
Kans. 7,249 - N 174 - -
S. ATLANTIC 163,936 - 5 430 35 -
Del. 3,035 - N 5 1 -
Md. 16,831 - 5 29 - -
D.C. 3,168 - - 14 8 -
Va. 19,439 - - 54 2 -
W. Va. 2,585 - N 4 - -
N.C. 26,187 - N 57 2 -
S.C. 14,623 - - 16 - -
Ga. 35,686 - - 122 8 -
Fla. 42,382 - N 129 14 -
E.S. CENTRAL 54,763 - 1 136 - -
Ky. 7,981 - N 27 N -
Tenn. 20,380 - N 43 - -
Ala. 14,209 - - 56 - -
Miss. 12,193 - 1 10 - -
W.S. CENTRAL 109,039 - 10 131 1 -
Ark. 7,856 - - 22 - -
La. 20,970 - - 5 - -
Okla. 11,013 - N 24 - -
Tex. 69,200 - 10 80 1 -
MOUNTAIN 48,934 1 2,751 139 - -
Mont. 2,547 - N 18 - -
Idaho 2,366 - N 27 - -
Wyo. 960 - 1 5 - -
Colo. 13,039 - N 38 - -
N. Mex. 7,480 - 10 17 - -
Ariz. 12,819 1 2,695 6 N -
Utah 3,893 - 9 20 - -
Nev. 5,830 - 36 8 - -
PACIFIC 151,293 1 2,091 386 - -
Wash. 16,797 - - 62 - -
Oreg. 7,688 - - 36 - -
Calif. 117,428 - 2,091 287 - -
Alaska 3,900 - - 1 - -
Hawaii 5,480 1 - - - -
Guam 598 - - - - -
P.R. 2,722 - N N N -
V.I. 410 - - - - -
Amer. Samoa - - - - - -
C.N.M.I. 218 - - - - -
N: Not Available. U: Unavailable. -: No reported cases.
* Totals reported to the Division of Sexually Transmitted Diseases Prevention, NCHSTP, as of May 1, 2004. Chlamydia refers to genital infections caused by Chlamydia trachomatis.
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TABLE 2. (Continued) Reported cases of notifiable diseases,* by geographic division and area — United States, 2003
Ehrlichiosis Encephalitis/meningitis, arboviral†
Human Human California Eastern
Area granulocytic monocytic serogroup equine St. Louis West Nile
UNITED STATES 362 321 108 14 41 2,866
NEW ENGLAND 151 37 - - - 31
Maine 4 - - - - -
N.H. 1 1 - - - 2
Vt. - - - - - -
Mass. 54 15 - - - 12
R.I. 63 21 - - - 5
Conn. 29 - - - - 12
MID. ATLANTIC 80 18 - 2 2 223
Upstate N.Y. 62 11 - - - -
N.Y. City 8 4 - - 1 57
N.J. 10 3 - 2 - 21
Pa. N N - - 1 145
E.N. CENTRAL 16 19 37 - 4 150
Ohio 2 6 17 - - 84
Ind. 1 6 - - - 15
Ill. 2 6 11 - - 30
Mich. - 1 - - 4 14
Wis. 11 - 9 - - 7
W.N. CENTRAL 88 34 3 - 1 696
Minn. 77 2 3 - - 48
Iowa 1 - - - - 81
Mo. 9 31 - - - 39
N. Dak. N N - - - 94
S. Dak. - - - - 1 151
Nebr. - - - - - 194
Kans. 1 1 - - - 89
S. ATLANTIC 23 119 42 9 - 191
Del. 9 3 - - - 12
Md. 5 51 - - - 49
D.C. N N - - - 3
Va. - 9 2 1 - 19
W. Va. - - 23 - - 1
N.C. 2 28 17 1 - 16
S.C. 2 - - 2 - 3
Ga. - 20 - 2 - 27
Fla. 5 8 - 3 - 61
E.S. CENTRAL 1 39 23 2 2 91
Ky. - 4 3 - - 11
Tenn. - 33 19 - - 21
Ala. 1 2 - 2 - 25
Miss. - - 1 - 2 34
W.S. CENTRAL 3 54 3 1 26 611
Ark. - 19 - - - 23
La. N N 3 1 9 101
Okla. 2 33 - - - 56
Tex. 1 2 - - 17 431
MOUNTAIN - 1 - - 6 871
Mont. - - - - - 75
Idaho - - - - - -
Wyo. - - - - - 92
Colo. N N - - - 621
N. Mex. - - - - 1 74
Ariz. - - - - 5 7
Utah - - - - - -
Nev. - 1 - - - 2
PACIFIC - - - - - 2
Wash. - - - - - -
Oreg. - - - - - -
Calif. - - - - - 2
Alaska - - - - - -
Hawaii - - - - - -
Guam - - - - - -
P.R. - - - - - -
V.I. - - - - - -
Amer. Samoa - - - - - -
C.N.M.I. - - - - - -
N: Not Available. U: Unavailable. -: No reported cases.
* No cases of Powassan or western equine encephalitis were reported in 2003.
†
Totals reported to the Division of Vector-Borne Infectious Diseases, NCID (ArboNet Surveillance).
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TABLE 2. (Continued) Reported cases of notifiable diseases, by geographic division and area — United States, 2003
Escherichia coli, enterohemorrhagic (EHEC) Haemophilus influenzae, invasive disease
Shiga toxin positive All ages Age <5 years
Non- Not All Serotype Non-serotype Unknown
Area O157:H7 O157 serogrouped Giardiasis Gonorrhea* serotypes b b serotype
UNITED STATES 2,671 252 156 19,709 335,104 2,013 32 117 227
NEW ENGLAND 163 47 13 1,700 7,443 176 2 7 6
Maine 11 4 - 186 233 6 - - 1
N.H. 21 3 - 44 125 20 1 2 -
Vt. 18 - - 122 97 11 - - 1
Mass. 72 10 13 854 2,901 80 1 5 3
R.I. 4 - - 126 973 15 - - 1
Conn. 37 30 - 368 3,114 44 - - -
MID. ATLANTIC 256 25 36 4,030 41,976 409 3 4 50
Upstate N.Y. 105 13 20 1,284 8,484 155 3 4 10
N.Y. City 7 - N 1,200 13,682 70 - - 13
N.J. 31 2 - 520 7,944 70 - - 11
Pa. 113 10 16 1,026 11,866 114 - - 16
E.N. CENTRAL 580 35 20 3,254 70,663 323 3 6 61
Ohio 132 16 20 903 22,537 78 - 1 14
Ind. 91 - - N 6,681 59 - - 11
Ill. 122 2 - 940 21,817 109 - - 24
Mich. 94 2 - 781 13,965 26 3 5 1
Wis. 141 15 - 630 5,663 51 - - 11
W.N. CENTRAL 451 56 22 2,161 18,147 125 2 8 14
Minn. 132 22 1 851 3,202 57 2 8 2
Iowa 104 - - 277 1,554 - - - -
Mo. 85 20 1 515 8,792 42 - - 11
N. Dak. 14 4 8 50 103 8 - - -
S. Dak. 29 4 - 89 226 1 - - -
Nebr. 51 6 - 145 1,623 2 - - -
Kans. 36 - 12 234 2,647 15 - - 1
S. ATLANTIC 168 51 48 2,883 81,875 453 2 20 33
Del. 11 N N 57 1,128 - - - -
Md. 18 3 1 118 8,032 109 1 9 1
D.C. 1 - - 61 2,508 2 - - -
Va. 50 15 - 423 9,066 68 - - 9
W. Va. 7 1 - 64 847 17 - - -
N.C. - - 38 N 15,116 41 - 3 2
S.C. 6 - - 175 8,518 13 - - 5
Ga. 27 8 - 853 17,686 81 - - 9
Fla. 48 24 9 1,132 18,974 122 1 8 7
E.S. CENTRAL 86 2 6 416 27,728 100 1 4 13
Ky. 29 2 6 N 3,578 12 - 3 2
Tenn. 36 - - 200 8,519 61 - 1 8
Ala. 17 - - 216 9,303 25 1 - 3
Miss. 4 - - - 6,328 2 - - -
W.S. CENTRAL 102 4 4 314 45,248 85 3 13 5
Ark. 13 - - 154 4,251 6 - 1 -
La. 3 - N 15 11,850 22 - 2 4
Okla. 30 - - 145 4,552 52 - 10 -
Tex. 56 4 4 N 24,595 5 3 - 1
MOUNTAIN 327 27 7 1,641 10,472 191 9 27 21
Mont. 17 - - 115 122 - - - -
Idaho 85 16 - 206 68 7 - - 3
Wyo. 5 1 - 23 46 2 - - -
Colo. 67 4 7 467 2,854 40 - - 7
N. Mex. 13 5 - 55 1,169 24 1 6 2
Ariz. 41 N N 256 3,580 93 8 11 5
Utah 75 - - 380 412 15 - 6 4
Nev. 24 1 - 139 2,221 10 - 4 -
PACIFIC 538 5 - 3,310 31,552 151 7 28 24
Wash. 128 1 - 435 2,753 14 3 7 3
Oreg. 102 4 - 411 1,000 42 - - 4
Calif. 294 - N 2,281 25,963 60 4 21 10
Alaska 5 - - 89 573 21 - - 7
Hawaii 9 - - 94 1,263 14 - - -
Guam - - - 2 68 - - - -
P.R. 3 - - 364 277 2 - - 2
V.I. - - - - 87 - - - -
Amer. Samoa - - - - 2 - - - -
C.N.M.I. - - - - 31 - - - -
N: Not Available. U: Unavailable. -: No reported cases.
* Totals reported to the Division of Sexually Transmitted Diseases Prevention, NCHSTP, as of May 1, 2004.
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TABLE 2. (Continued) Reported cases of notifiable diseases, by geographic division and area — United States, 2003
Hemolytic
Hansen Hantavirus uremic
disease pulmonary syndrome, Hepatitis, acute viral
Area  (leprosy) syndrome postdiarrheal A B C Legionellosis Listeriosis
UNITED STATES 95 26 178 7,653 7,526 1,102 2,232 696
NEW ENGLAND 4 - 11 370 367 17 122 57
Maine N - - 21 7 3 2 7
N.H. - - - 19 24 N 9 4
Vt. - - 1 6 4 13 6 1
Mass. 4 - 8 217 213 - 57 19
R.I. - - - 17 21 1 20 4
Conn. - N 2 90 98 - 28 22
MID. ATLANTIC 12 - 23 1,821 780 143 632 139
Upstate N.Y. 1 - 18 146 110 26 176 44
N.Y. City 8 - - 450 193 - 71 24
N.J. 3 - 3 208 183 - 94 24
Pa. - - 2 1,017 294 117 291 47
E.N. CENTRAL 3 - 17 681 634 127 459 92
Ohio 2 - 5 171 160 9 226 27
Ind. - - 1 73 70 12 34 10
Ill. - - 3 186 130 22 50 24
Mich. 1 - 4 206 223 79 131 21
Wis. - - 4 45 51 5 18 10
W.N. CENTRAL 2 5 27 195 377 285 75 20
Minn. 1 - 9 52 55 23 5 6
Iowa - 1 2 40 18 1 12 1
Mo. - - 8 60 248 258 37 6
N. Dak. N - 1 2 2 - 1 -
S. Dak. - 1 1 - 4 - 2 -
Nebr. 1 1 6 14 32 3 7 4
Kans. - 2 - 27 18 - 11 3
S. ATLANTIC 10 - 13 1,781 2,090 165 553 150
Del. - - - 9 14 - 31 N
Md. 1 - N 178 132 9 134 27
D.C. - - - 43 13 - 19 2
Va. - - 1 141 227 15 109 18
W. Va. N - 1 38 43 20 26 7
N.C. - - 3 126 163 13 42 18
S.C. - - - 56 201 26 11 9
Ga. N - 2 791 666 13 34 31
Fla. 9 - 6 399 631 69 147 38
E.S. CENTRAL 1 - 14 282 531 100 108 33
Ky. - - N 36 94 26 46 9
Tenn. 1 - 14 206 229 25 37 9
Ala. - - - 24 96 6 20 13
Miss. - - - 16 112 43 5 2
W.S. CENTRAL 24 5 8 729 1,249 161 84 50
Ark. 3 - - 38 91 3 2 1
La. 2 N - 50 117 102 1 5
Okla. - - 4 28 76 6 10 3
Tex. 19 5 4 613 965 50 71 41
MOUNTAIN 3 12 15 486 595 53 90 34
Mont. - - - 8 16 4 4 2
Idaho - 2 1 18 8 1 7 2
Wyo. - 1 - 2 31 - 2 -
Colo. - 4 8 63 82 14 12 9
N. Mex. - 1 - 25 36 - 5 3
Ariz. 1 - N 280 283 7 21 12
Utah 1 3 5 39 52 - 27 2
Nev. 1 1 1 51 87 27 12 4
PACIFIC 36 4 50 1,308 903 51 109 121
Wash. N 2 - 76 90 - 14 13
Oreg. N - 7 62 121 16 17 5
Calif. 21 2 42 1,147 657 31 77 98
Alaska - - - 10 8 - - -
Hawaii 15 - 1 13 27 4 1 5
Guam 11 - - 2 10 5 1 -
P.R. 1 N N 102 144 - - -
V.I. - - - - - - - -
Amer. Samoa - - - 1 5 - - -
C.N.M.I. - - - - 1 - - -
N: Not Available. U: Unavailable. -: No reported cases.
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TABLE 2. (Continued) Reported cases of notifiable diseases, by geographic division and area — United States, 2003
Lyme Measles Meningococcal
Area disease Malaria Indigenous Imported* disease Mumps Pertussis Plague
UNITED STATES 21,273 1,402 32 24 1,756 231 11,647 1
NEW ENGLAND 4,079 74 1 - 86 4 2,083 -
Maine 175 5 - - 6 - 91 -
N.H. 190 7 1 - 12 2 119 -
Vt. 43 2 - - 4 - 71 -
Mass. 1,532 32 - - 45 1 1,670 -
R.I. 736 7 - - 4 - 55 -
Conn. 1,403 21 - - 15 1 77 -
MID. ATLANTIC 14,016 368 14 4 210 30 1,757 -
Upstate N.Y. 5,179 63 2 - 55 3 1,067 -
N.Y. City 220 194 3 2 43 12 150 -
N.J. 2,887 61 1 1 31 6 188 -
Pa. 5,730 50 8 1 81 9 352 -
E.N. CENTRAL 914 109 3 3 262 28 1,590 -
Ohio 66 23 1 1 60 7 328 -
Ind. 25 4 - - 48 3 104 -
Ill. 71 46 - 1 73 8 321 -
Mich. 12 25 2 - 50 8 140 -
Wis. 740 11 - 1 31 2 697 -
W.N. CENTRAL 609 57 - - 131 11 657 -
Minn. 474 28 - - 29 1 207 -
Iowa 58 6 - - 28 2 166 -
Mo. 70 7 - - 49 5 208 -
N. Dak. - 1 - - 1 - 7 -
S. Dak. 1 3 - - 1 - 7 -
Nebr. 2 - - - 8 - 16 -
Kans. 4 12 - - 15 3 46 -
S. ATLANTIC 1,370 351 - 3 287 28 855 -
Del. 212 2 - - 9 2 9 -
Md. 691 80 - 1 28 5 94 -
D.C. 14 17 - - 6 - 4 -
Va. 195 59 - - 28 1 219 -
W. Va. 31 4 - - 7 3 28 -
N.C. 156 25 - 1 37 2 144 -
S.C. 18 5 - - 29 5 208 -
Ga. 10 67 - 1 37 3 36 -
Fla. 43 92 - - 106 7 113 -
E.S. CENTRAL 66 32 - - 97 10 170 -
Ky. 17 11 - - 23 - 53 -
Tenn. 20 7 - - 30 5 83 -
Ala. 8 7 - - 21 4 19 -
Miss. 21 7 - - 23 1 15 -
W.S. CENTRAL 92 139 - - 193 22 879 -
Ark. - 4 - - 21 1 92 -
La. 7 5 - - 43 1 11 -
Okla. - 5 - - 24 2 106 -
Tex. 85 125 - - 105 18 670 -
MOUNTAIN 15 54 - 1 103 15 1,040 1
Mont. - - - - 6 - 5 -
Idaho 3 1 - - 9 1 82 -
Wyo. 2 2 - - 2 1 130 -
Colo. - 23 - - 27 1 372 -
N. Mex. 1 3 - - 12 1 78 1
Ariz. 4 17 - 1 34 1 211 -
Utah 2 6 - - 5 5 127 -
Nev. 3 2 - - 8 5 35 -
PACIFIC 112 218 14 13 387 83 2,616 -
Wash. 7 34 - - 61 11 844 -
Oreg. 16 11 - 3 63 N 438 -
Calif. 86 166 - 5 242 58 1,255 -
Alaska 3 1 - - 7 1 67 -
Hawaii N 6 14 5 14 13 12 -
Guam - 1 5 - - 3 1 -
P.R. N 2 - - 12 2 5 -
V.I. - - - - - - - -
Amer. Samoa - - 1 - - 1 - -
C.N.M.I. - - - - - - - -
N: Not Available. U: Unavailable. -: No reported cases.
* Imported cases include only those directly related to importation from other countries.
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TABLE 2. (Continued) Reported cases of notifiable diseases,* by geographic division and area — United States, 2003
Rubella
Rabies Congenital SARs§
Area Psittacosis Q Fever Animal Human RMSF† Rubella syndrome Salmonellosis CoV
UNITED STATES 12 71 6,846 2 1,091 7 1 43,657 8
NEW ENGLAND 1 6 616 - 10 1 - 2,127 -
Maine - 2 73 - N - - 141 -
N.H. 1 - 29 - - - - 152 -
Vt. - - 39 - - - - 73 -
Mass. - 4 216 - 9 1 - 1,223 -
R.I. - - 71 - 1 - - 137 -
Conn. N - 188 - - - - 401 -
MID. ATLANTIC 2 2 929 - 41 3 1 4,995 2
Upstate N.Y. - - 432 - - - - 1,282 -
N.Y. City - 2 6 - 13 1 1 1,301 -
N.J. - - 62 - 16 2 - 857 1
Pa. 2 N 429 - 12 - - 1,555 1
E.N. CENTRAL - 12 175 - 22 - - 5,614 -
Ohio - 8 53 - 10 - - 1,326 -
Ind. - 2 32 - 1 - - 587 -
Ill. - - 24 - 5 - - 1,955 -
Mich. - 1 52 - 6 - - 798 -
Wis. - 1 14 - - - - 948 -
W.N. CENTRAL - 7 646 - 65 - - 2,525 -
Minn. - 1 48 - 2 - - 574 -
Iowa - - 105 - 2 - - 415 -
Mo. - 3 43 - 51 - - 882 -
N. Dak. - 1 57 - - - - 46 -
S. Dak. - - 132 - 5 - - 131 -
Nebr. - 1 98 - 4 - - 183 -
Kans. - 1 163 - 1 - - 294 -
S. ATLANTIC 6 12 2,657 1 610 - - 11,382 2
Del. - N 64 - 1 - - 105 -
Md. - - 351 - 106 - - 856 -
D.C. - 2 - - 1 - - 55 -
Va. 1 - 542 1 34 - - 1,187 1
W. Va. - N 82 - 6 - - 152 -
N.C. - 2 773 - 331 - - 1,435 1
S.C. 2 1 255 - 49 - - 866 -
Ga. - 1 402 - 65 - - 2,057 -
Fla. 3 6 188 - 17 - - 4,669 -
E.S. CENTRAL - 15 210 - 131 - - 2,979 -
Ky. - 9 39 - 3 - - 404 -
Tenn. - 6 103 - 74 - - 781 -
Ala. - - 64 - 21 - - 792 -
Miss. - - 4 - 33 - - 1,002 -
W.S. CENTRAL - 4 1,200 - 201 - - 6,079 -
Ark. - - 69 - 48 - - 838 -
La. - - 5 - 1 - - 879 -
Okla. - N 204 - 138 - - 494 -
Tex. N 4 922 - 14 - - 3,868 -
MOUNTAIN 1 3 181 - 10 1 - 2,379 2
Mont. - - 23 - 1 - - 112 -
Idaho 1 1 15 - 2 - - 181 -
Wyo. - - 6 - 2 - - 77 -
Colo. - - 38 - 3 1 - 503 -
N. Mex. - - 5 - 1 - - 304 1
Ariz. - - 75 - - - - 789 -
Utah - - 14 - 1 - - 234 1
Nev. - 2 5 - - - - 179 -
PACIFIC 2 10 232 1 1 2 - 5,577 2
Wash. - - - - N - - 699 -
Oreg. 1 1 7 - - 1 - 425 -
Calif. 1 9 216 1 1 - - 4,127 2
Alaska - - 9 - - - - 96 -
Hawaii - - - - - 1 - 230 -
Guam - - - - - 1 - 44 -
P.R. N - 71 1 N - - 798 -
V.I. - - - - - - - - -
Amer. Samoa - - - - - - - - -
C.N.M.I. - - - - - - - 21 -
N: Not Available. U: Unavailable. -: No reported cases.
* No cases of paralytic poliomyelitis were reported in 2003.
†
Rocky Mountain spotted fever.
§
Totals reported to the Division of Viral and Rickettsial Diseases, National Center for Infectious Diseases.
Vol. 53 / No. 30 MMWR 695
TABLE 2. (Continued) Reported cases of notifiable diseases, by geographic division and area — United States, 2003
Streptococcal Streptococcus Streptococcus
disease, Streptococcal pneumoniae, pneumoniae, Syphilis*
invasive, toxic-shock invasive, invasive, Congenital Primary &
Area Shigellosis group A syndrome drug-resistant (<5 years) All  stages† (age <1 yr) secondary
UNITED STATES 23,581 5,872 161 2,356 845 34,270 413 7,177
NEW ENGLAND 353 488 7 123 17 1,000 1 224
Maine 7 29 - - - 21 - 8
N.H. 10 34 - - N 37 - 19
Vt. 8 19 3 9 5 1 - 1
Mass. 236 210 2 N N 644 - 133
R.I. 22 35 2 25 12 90 - 33
Conn. 70 161 U 89 U 207 1 30
MID. ATLANTIC 2,399 953 8 152 92 6,155 65 913
Upstate N.Y. 645 362 - 88 88 535 12 53
N.Y. City 416 146 - U U 3,825 30 531
N.J. 360 174 1 - 4 1,089 21 170
Pa. 978 271 7 64 N 706 2 159
E.N. CENTRAL 1,882 1,305 106 475 331 3,203 75 886
Ohio 301 287 24 285 98 481 3 197
Ind. 201 136 14 190 38 375 15 50
Ill. 1,006 349 68 - 134 1,376 19 374
Mich. 235 357 N N N 860 38 249
Wis. 139 176 - N 61 111 - 16
W.N. CENTRAL 796 363 11 188 91 559 6 159
Minn. 103 181 9 167 74 195 - 47
Iowa 94 N - N N 46 - 12
Mo. 356 81 2 16 3 207 4 61
N. Dak. 10 18 - 4 9 2 - 2
S. Dak. 17 25 - 1 - 5 - 2
Nebr. 92 27 - - 5 27 1 10
Kans. 124 31 - N N 77 1 25
S. ATLANTIC 6,973 987 11 1,149 85 8,744 76 1,940
Del. 164 8 - N N 47 - 7
Md. 579 233 N 27 - 974 8 312
D.C. 76 11 - 1 9 330 1 48
Va. 453 111 3 N N 552 1 82
W. Va. 4 39 4 113 12 11 - 2
N.C. 1,061 111 4 N U 848 18 152
S.C. 620 50 - 153 N 548 11 94
Ga. 1,169 195 N 249 64 2,152 11 585
Fla. 2,847 229 N 606 N 3,282 26 658
E.S. CENTRAL 1,058 222 7 168 - 2,037 8 322
Ky. 136 52 6 31 N 160 1 33
Tenn. 405 170 1 137 N 876 2 135
Ala. 342 - - - N 566 3 114
Miss. 175 - - - - 435 2 40
W.S. CENTRAL 6,047 315 - 85 155 6,221 81 952
Ark. 113 7 - 24 8 296 2 51
La. 447 2 - 61 30 1,576 1 183
Okla. 1,078 99 N N 77 353 1 64
Tex. 4,409 207 - N 40 3,996 77 654
MOUNTAIN 1,354 598 11 12 74 1,725, 42 337
Mont. 2 1 - - - - - -
Idaho 36 19 2 N N 45 4 15
Wyo. 8 2 1 10 - 4 - -
Colo. 333 147 4 - 55 144 3 39
N. Mex. 286 127 - - 12 205 6 71
Ariz. 572 259 - N N 1,106 29 186
Utah 51 41 3 2 7 72 - 14
Nev. 66 2 1 - - 149 - 12
PACIFIC 2,719 641 - 4 - 4,626 59 1,444
Wash. 188 74 - - N 239 - 82
Oreg. 211 N - N N 118 - 48
Calif. 2,261 428 - N N 4,202 59 1,299
Alaska 11 - - - N 8 - 1
Hawaii 48 139 - 4 - 59 - 14
Guam 41 - - - - 2 1 1
P.R. 33 N N N N 1,391 15 204
V.I. - - - - - 1 - 1
Amer. Samoa 6 - - - - 1 - 1
C.N.M.I. 128 - - - - 8 - 8
N: Not Available. U: Unavailable. -: No reported cases.
* Totals reported to the Division of Sexually Transmitted Diseases Prevention, NCHSTP, as of May 1, 2004.
†
Includes the following categories: primary, secondary, early, late (including neurosyphilis, late latent, late with clinical manifestations, and unknown latent), and congenital
syphilis.
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TABLE 2. (Continued) Reported cases of notifiable diseases,* by geographic division and area — United States, 2003
Toxic-shock Typhoid Varicella Varicella
Area Tetanus syndrome Trichinosis Tuberculosis† Tularemia fever (chickenpox) deaths§
UNITED STATES 20 133 6 14,883 129 356 20,948 2
NEW ENGLAND 1 8 1 467 6 29 5,522 -
Maine - 1 - 25 - - 1,012 -
N.H. - 2 1 15 - 4 - -
Vt. 1 1 - 9 - - 930 -
Mass. - 3 - 261 6 15 1,993 -
R.I. - 1 - 46 - 2 5 -
Conn. - N - 111 - 8 1,582 -
MID. ATLANTIC 1 16 1 2,311 1 80 43 -
Upstate N.Y. 1 6 1 340 1 12 - -
N.Y. City - 1 - 1,140 - 37 - -
N.J. - - - 495 - 21 - -
Pa. - 9 - 336 - 10 43 -
E.N. CENTRAL 3 39 - 1,314 2 33 6,484 -
Ohio 2 12 - 229 - 2 1,302 -
Ind. 1 2 - 143 - 4 - -
Ill. - 9 - 633 1 17 - -
Mich. - 13 - 243 - 10 4,171 -
Wis. - 3 - 66 1 - 1,011 -
W.N. CENTRAL 1 29 - 514 46 7 103 -
Minn. - 10 - 214 1 3 N -
Iowa - 5 - 40 N 2 N -
Mo. - 4 - 131 32 1 1 -
N. Dak. - 1 - 6 - - 102 -
S. Dak. - 1 - 20 5 - - -
Nebr. 1 7 - 28 5 1 N -
Kans. - 1 - 75 3 - - -
S. ATLANTIC 5 10 - 2,933 9 59 2,433 1
Del. - - - 33 3 - 29 -
Md. 1 N - 268 1 11 1 1
D.C. 1 1 - 79 - - 55 -
Va. - 3 - 332 4 16 682 -
W. Va. - - - 21 - - 1,330 -
N.C. - 2 - 374 1 9 N -
S.C. - - - 254 - - 336 -
Ga. - 4 N 526 - 8 N -
Fla. 3 N - 1,046 - 15 N -
E.S. CENTRAL 3 2 2 809 7 8 - -
Ky. - - N 138 2 1 N -
Tenn. 1 1 2 285 3 3 - -
Ala. 1 1 - 258 1 4 - -
Miss. 1 - - 128 1 - - -
W.S. CENTRAL 1 - - 2,144 43 31 5,481 1
Ark. - - - 127 32 - - 1
La. - - - 260 - - 16 -
Okla. - - - 163 9 1 N -
Tex. 1 N - 1,594 2 30 5,465 -
MOUNTAIN - 19 - 625 10 8 882 -
Mont. - - - 7 - - - -
Idaho - - - 13 - 1 - -
Wyo. - - - 4 3 - 113 -
Colo. - 5 - 111 3 4 N -
N. Mex. - 1 - 49 1 1 7 -
Ariz. - 9 - 295 1 2 N -
Utah - 2 - 39 2 - 762 -
Nev. - 2 - 107 - - - -
PACIFIC 5 10 2 3,757 5 101 - -
Wash. - - - 250 3 4 N -
Oreg. - - - 106 - 4 N -
Calif. 5 10 2 3,227 2 91 N -
Alaska - - - 57 - - - -
Hawaii - - - 117 - 2 - -
Guam - - - 61 - - 153 -
P.R. - N - 115 - - 626 -
V.I. - - - - - - - -
Amer. Samoa - - - - - 1 21 -
C.N.M.I. - - - 45 - - - -
N: Not Available. U: Unavailable. -: No reported cases.
* No cases of yellow fever were reported in 2003.
†
Totals reported to the Division of Tuberculosis Elimination, NCHSTP, as of April 1, 2004.
§
Death counts provided by the Epidemiology and Surveillance Division, National Immunization Program.
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* No measles cases were reported for the current 4-week period yielding a ratio for week 30 of zero (0).
† Ratio of current 4-week total to mean of 15 4-week totals (from previous, comparable, and subsequent 4-week periods for the past 5 years). The point where the hatched area
begins is based on the mean and two standard deviations of these 4-week totals.
-: No reported cases.
* Incidence data for reporting years 2003 and 2004 are provisional and cumulative (year-to-date).
†
Not notifiable in all states.
§
Updated weekly from reports to the Division of Vector-Borne Infectious Diseases, National Center for Infectious Diseases (ArboNet Surveillance).
¶
Updated monthly from reports to the Division of HIV/AIDS Prevention — Surveillance and Epidemiology, National Center for HIV, STD, and TB Prevention.
Last update June 27, 2004.
** Of 18 cases reported, 10 were indigenous, and eight were imported from another country.
††
Of 37 cases reported, 25 were indigenous, and 12 were imported from another country.
§§
Updated weekly from reports to the Division of Viral and Rickettsial Diseases, National Center for Infectious Diseases (notifiable as of July 2003).
¶¶
Not previously notifiable.
TABLE I. Summary of provisional cases of selected notifiable diseases, United States, cumulative, week ending July 31, 2004 (30th Week)*
Cum. Cum. Cum. Cum.
2004 2003 2004 2003
Anthrax - - Hemolytic uremic syndrome, postdiarrheal† 60 79
Botulism: - - HIV infection, pediatric†¶ 88 130
foodborne 8 8 Measles, total 18** 37††
infant 41 38 Mumps 121 128
other (wound & unspecified) 8 16 Plague - 1
Brucellosis† 63 52 Poliomyelitis, paralytic - -
Chancroid 18 36 Psittacosis† 5 6
Cholera 4 1 Q fever† 30 46
Cyclosporiasis† 108 45 Rabies, human 3 -
Diphtheria - - Rubella 15 6
Ehrlichiosis: - - Rubella, congenital syndrome - 1
human granulocytic (HGE)† 108 119 SARS-associated coronavirus disease† §§ - 7
human monocytic (HME)† 85 104 Smallpox†  ¶¶ - NA
human, other and unspecified 3 20 Staphylococcus aureus: - -
Encephalitis/Meningitis: - -           Vancomycin-intermediate (VISA)†  ¶¶ 4 NA
California serogroup viral† § 11 30           Vancomycin-resistant (VRSA)†  ¶¶ 1 NA
eastern equine† § - 8 Streptococcal toxic-shock syndrome† 63 118
Powassan† § - - Tetanus 7 5
St. Louis† § - 7 Toxic-shock syndrome 58 75
western equine† § - - Trichinosis 5 -
Hansen disease (leprosy)† 44 50 Tularemia† 38 39
Hantavirus pulmonary syndrome† 10 14 Yellow fever - -
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N: Not notifiable. U: Unavailable. -: No reported cases. C.N.M.I.: Commonwealth of Northern Mariana Islands.
* Incidence data for reporting years 2003 and 2004 are provisional and cumulative (year-to-date).
† Chlamydia refers to genital infections caused by C. trachomatis.
§ Updated weekly from reports to the Division of Vector-Borne Infectious Diseases, National Center for Infectious Diseases (ArboNet Surveillance).
¶ Updated monthly from reports to the Division of HIV/AIDS Prevention — Surveillance and Epidemiology, National Center for HIV, STD, and TB Prevention. Last update
June 27, 2004.
** Contains data reported through National Electronic Disease Surveillance System (NEDSS).
TABLE II. Provisional cases of selected notifiable diseases, United States, weeks ending July 31, 2004, and July 26, 2003
(30th Week)*
Encephalitis/Meningitis
AIDS Chlamydia† Coccidiodomycosis  Cryptosporidiosis  West Nile§
Cum. Cum. Cum. Cum. Cum. Cum. Cum. Cum. Cum. Cum.
Reporting area 2004¶ 2003 2004 2003 2004 2003 2004 2003 2004 2003
UNITED STATES 20,281 24,155 486,420 489,036 3,142 1,913 1,370 1,259 155 286
NEW ENGLAND 727 843 16,670 15,621 - - 81 87 - 1
Maine 10 35 1,131 1,114 N N 14 6 - -
N.H. 26 22 890 881 - - 16 11 - 1
Vt. 13 11 567 577 - - 12 18 - -
Mass. 235 371 7,827 6,076 - - 25 40 - -
R.I. 70 68 1,881 1,667 - - 2 9 - -
Conn. 373 336 4,374 5,306 N N 12 3 - -
MID. ATLANTIC 4,432 5,185 61,950 60,743 - - 210 172 3 12
Upstate N.Y. 591 623 12,796 11,014 N N 55 43 - -
N.Y. City 2,341 2,408 18,794 19,951 - - 48 60 2 -
N.J. 788 949 10,050 9,137 - - 12 9 - -
Pa. 712 1,205 20,310 20,641 N N 95 60 1 12
E.N. CENTRAL 1,724 2,383 81,393 88,162 7 4 328 331 2 11
Ohio 237 419 19,679 23,983 - - 85 44 1 7
Ind. 219 306 10,257 9,681 N N 39 33 - 3
Ill. 852 1,117 21,714 27,250 - - 13 43 - 1
Mich. 326 417 20,831 17,481 7 4 77 55 1 -
Wis. 90 124 8,912 9,767 - - 114 156 - -
W.N. CENTRAL 407 431 29,514 28,271 4 2 199 143 2 51
Minn. 95 96 5,413 6,162 N N 68 53 - 2
Iowa 28 45 3,136 3,278 N N 37 28 - 6
Mo. 181 203 11,439 10,167 3 1 36 14 1 -
N. Dak. 12 3 900 888 N N 8 10 - 4
S. Dak. 6 6 1,421 1,416 - - 23 22 1 19
Nebr.** 18 30 2,971 2,421 1 1 14 6 - 13
Kans. 67 48 4,234 3,939 N N 13 10 - 7
S. ATLANTIC 6,151 6,972 94,070 91,196 - 3 247 167 4 10
Del. 83 133 1,616 1,754 N N - 3 - -
Md. 690 867 10,759 9,288 - 3 10 9 - -
D.C. 354 656 1,716 1,861 - - 6 3 - -
Va. 336 593 12,697 10,762 - - 27 16 - 2
W. Va. 31 49 1,620 1,426 N N 3 3 - -
N.C. 344 634 15,979 14,386 N N 43 19 - 1
S.C.** 376 466 9,215 7,965 - - 9 2 - 1
Ga. 894 953 16,218 19,904 - - 79 63 - -
Fla. 3,043 2,621 24,250 23,850 N N 70 49 4 6
E.S. CENTRAL 958 1,102 31,347 31,639 2 1 56 63 2 13
Ky. 107 98 3,265 4,633 N N 22 13 - 1
Tenn.** 391 477 12,693 11,325 N N 12 24 - 1
Ala. 233 271 6,203 8,449 - - 13 23 2 5
Miss. 227 256 9,186 7,232 2 1 9 3 - 6
W.S. CENTRAL 2,544 2,691 62,707 61,297 2 - 40 33 3 110
Ark. 124 106 4,483 4,396 1 - 12 5 1 2
La. 576 402 12,916 12,509 1 - - 2 - 25
Okla. 90 135 6,349 6,238 N N 13 6 - 5
Tex. 1,754 2,048 38,959 38,154 - - 15 20 2 78
MOUNTAIN 729 920 25,246 28,614 1,983 1,272 71 63 111 78
Mont. 5 10 1,269 1,276 N N 15 12 - -
Idaho 9 16 1,668 1,380 N N 8 14 - -
Wyo. 7 5 598 552 - 1 2 2 - 3
Colo. 137 212 5,177 7,292 N N 28 13 9 72
N. Mex. 107 70 2,586 4,242 9 5 4 4 1 3
Ariz. 284 392 9,411 8,453 1,920 1,242 11 3 99 -
Utah 34 40 2,065 2,119 18 4 2 9 - -
Nev. 146 175 2,472 3,300 36 20 1 6 2 -
PACIFIC 2,609 3,628 83,523 83,493 1,144 631 138 200 28 -
Wash. 214 271 10,023 9,053 N N 14 25 - -
Oreg. 133 146 4,752 4,317 - - 18 25 - -
Calif. 2,201 3,136 65,068 64,882 1,144 631 105 150 28 -
Alaska 15 13 2,040 2,198 - - - - - -
Hawaii 46 62 1,640 3,043 - - 1 - - -
Guam 2 5 - 395 - - - - - -
P.R. 209 620 1,474 1,369 N N N N - -
V.I. 6 17 143 217 - - - - - -
Amer. Samoa U U U U U U U U U U
C.N.M.I. 2 U 32 U - U - U - U
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N: Not notifiable. U: Unavailable. - : No reported cases.
* Incidence data for reporting years 2003 and 2004 are provisional and cumulative (year-to-date).
TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending July 31, 2004, and July 26, 2003
(30th Week)*
Escherichia coli, Enterohemorrhagic (EHEC)
Shiga toxin positive, Shiga toxin positive,
 O157:H7  serogroup non-O157 not serogrouped Giardiasis Gonorrhea
Cum. Cum. Cum. Cum. Cum. Cum.  Cum. Cum. Cum. Cum.
Reporting area 2004 2003 2004 2003 2004 2003 2004 2003 2004 2003
UNITED STATES 1,024 974 107 109 86 69 8,582 9,153 169,216 184,094
NEW ENGLAND 69 57 28 22 14 5 735 663 3,947 3,883
Maine 3 5 - - - - 72 72 140 123
N.H. 10 10 5 2 - - 18 23 64 63
Vt. 6 5 - - 1 - 74 49 47 48
Mass. 32 21 4 7 13 5 333 326 1,850 1,475
R.I. 5 1 1 - - - 54 55 501 510
Conn. 13 15 18 13 - - 184 138 1,345 1,664
MID. ATLANTIC 120 121 16 10 16 16 1,947 1,903 19,943 23,243
Upstate N.Y. 54 41 8 4 6 7 647 468 4,235 4,278
N.Y. City 24 3 - - - - 571 657 6,078 7,655
N.J. 16 19 3 1 4 - 201 277 3,894 4,887
Pa. 26 58 5 5 6 9 528 501 5,736 6,423
E.N. CENTRAL 194 237 21 19 11 9 1,052 1,631 33,251 38,657
Ohio 49 44 7 10 11 9 424 460 9,783 12,460
Ind. 15 41 - - - - - - 3,568 3,645
Ill. 34 43 - 2 - - 84 513 9,253 11,939
Mich. 45 36 4 - - - 358 365 8,360 7,306
Wis. 51 73 10 7 - - 186 293 2,287 3,307
W.N. CENTRAL 231 168 17 17 17 9 1,006 917 9,351 9,617
Minn. 45 52 7 8 2 - 346 340 1,816 1,604
Iowa 65 35 - - - - 144 124 556 769
Mo. 50 44 10 2 6 1 270 257 4,731 4,891
N. Dak. 6 6 - 3 7 2 17 23 66 37
S. Dak. 18 10 - 3 - - 34 24 154 115
Nebr. 31 8 - 1 - - 71 67 582 763
Kans. 16 13 - - 2 6 124 82 1,446 1,438
S. ATLANTIC 82 72 15 26 19 17 1,422 1,384 41,942 45,066
Del. 1 2 N N N N 27 19 522 681
Md. 18 3 1 1 3 1 60 60 4,691 4,399
D.C. 1 1 - - - - 35 20 1,249 1,413
Va. 16 21 6 5 - - 234 203 5,165 5,000
W. Va. 1 2 - - - - 17 23 513 486
N.C. - - - - 10 15 N N 8,466 8,328
S.C. 4 - - - - - 28 67 4,373 4,574
Ga. 16 15 4 3 - - 398 440 6,912 9,717
Fla. 25 28 4 17 6 1 623 552 10,051 10,468
E.S. CENTRAL 46 42 1 - 8 5 170 183 13,429 15,432
Ky. 17 13 1 - 5 5 N N 1,416 1,984
Tenn. 15 17 - - 3 - 79 83 4,661 4,553
Ala. 8 9 - - - - 91 100 3,875 5,234
Miss. 6 3 - - - - - - 3,477 3,661
W.S. CENTRAL 43 42 1 3 1 4 140 156 23,393 25,178
Ark. 8 5 - - - - 63 84 2,153 2,366
La. 2 1 - - - - 19 8 5,807 7,045
Okla. 10 12 - - - - 58 64 2,662 2,435
Tex. 23 24 1 3 1 4 - - 12,771 13,332
MOUNTAIN 94 112 7 10 - 4 732 758 5,415 6,028
Mont. 10 4 - - - - 24 43 38 65
Idaho 22 26 3 6 - - 91 84 47 40
Wyo. 1 2 1 - - - 13 11 28 26
Colo. 21 32 1 2 - 4 249 218 1,547 1,657
N. Mex. 5 4 - 2 - - 41 27 313 693
Ariz. 10 18 N N N N 105 141 2,012 2,250
Utah 16 20 1 - - - 153 161 313 191
Nev. 9 6 1 - - - 56 73 1,117 1,106
PACIFIC 145 123 1 2 - - 1,378 1,558 18,545 16,990
Wash. 51 33 - 1 - - 177 152 1,499 1,583
Oreg. 18 20 1 1 - - 229 203 634 583
Calif. 68 69 - - - - 891 1,107 15,689 13,885
Alaska 1 1 - - - - 36 47 322 305
Hawaii 7 - - - - - 45 49 401 634
Guam N N - - - - - - - 40
P.R. - 1 - - - - 17 132 119 152
V.I. - - - - - - - - 49 53
Amer. Samoa U U U U U U U U U U
C.N.M.I. - U - U - U - U 3 U
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N: Not notifiable. U: Unavailable. -: No reported cases.
* Incidence data for reporting years 2003 and 2004 are provisional and cumulative (year-to-date).
TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending July 31, 2004, and July 26, 2003
(30th Week)*
Haemophilus influenzae, invasive Hepatitis
All ages Age <5 years (viral, acute), by type
All serotypes Serotype b Non-serotype b Unknown serotype A
Cum. Cum. Cum. Cum. Cum. Cum. Cum. Cum. Cum. Cum.
Reporting area 2004 2003 2004 2003 2004 2003 2004 2003 2004 2003
UNITED STATES 1,131 1,132 10 16 54 74 110 130 3,068 3,618
NEW ENGLAND 102 73 1 1 5 5 3 3 519 168
Maine 7 2 - - - - - 1 10 7
N.H. 13 8 - - 2 - - - 11 9
Vt. 5 6 - - - - 1 - 8 4
Mass. 46 41 1 1 - 5 2 1 445 87
R.I. 3 4 - - - - - 1 10 11
Conn. 28 12 - - 3 - - - 35 50
MID. ATLANTIC 243 245 - 1 3 2 28 31 365 765
Upstate N.Y. 82 85 - 1 3 2 4 7 53 65
N.Y. City 50 44 - - - - 9 8 141 279
N.J. 45 49 - - - - 3 7 69 117
Pa. 66 67 - - - - 12 9 102 304
E.N. CENTRAL 185 190 - 3 6 3 27 35 276 364
Ohio 69 45 - - 2 - 11 7 32 72
Ind. 34 32 - - 4 - 1 3 15 35
Ill. 41 70 - - - - 9 18 109 105
Mich. 14 15 - 3 - 3 5 1 97 117
Wis. 27 28 - - - - 1 6 23 35
W.N. CENTRAL 66 75 2 - 3 6 4 9 119 105
Minn. 28 27 1 - 3 6 - 1 28 33
Iowa 1 - 1 - - - - - 31 16
Mo. 21 32 - - - - 2 8 38 32
N. Dak. 3 2 - - - - - - 1 -
S. Dak. - 1 - - - - - - 2 -
Nebr. 6 1 - - - - - - 8 7
Kans. 7 12 - - - - 2 - 11 17
S. ATLANTIC 269 230 - - 16 9 19 15 588 771
Del. 6 - - - - - - - 5 5
Md. 44 55 - - 4 5 1 - 78 79
D.C. - - - - - - - - 4 25
Va. 24 31 - - - - 1 5 56 47
W. Va. 10 9 - - - - 3 - 2 12
N.C. 40 20 - - 5 1 1 1 55 42
S.C. 2 5 - - - - - 1 21 23
Ga. 71 43 - - - - 12 5 204 311
Fla. 72 67 - - 7 3 1 3 163 227
E.S. CENTRAL 41 47 1 1 - 2 8 4 89 105
Ky. 3 3 - - - 1 - - 16 19
Tenn. 26 27 - - - 1 6 3 49 61
Ala. 12 16 1 1 - - 2 1 6 12
Miss. - 1 - - - - - - 18 13
W.S. CENTRAL 46 54 1 1 5 8 1 4 222 357
Ark. 1 5 - - - 1 - - 38 20
La. 8 17 - - - 2 1 4 15 33
Okla. 36 30 - - 5 5 - - 17 8
Tex. 1 2 1 1 - - - - 152 296
MOUNTAIN 131 118 3 6 15 19 14 13 269 273
Mont. - - - - - - - - 4 3
Idaho 5 3 - - - - 2 1 12 9
Wyo. - 1 - - - - - - 4 1
Colo. 30 23 - - - - 3 5 29 40
N. Mex. 25 15 - - 5 4 3 1 10 11
Ariz. 50 61 - 6 7 8 2 4 169 155
Utah 10 9 2 - 1 4 2 2 34 18
Nev. 11 6 1 - 2 3 2 - 7 36
PACIFIC 48 100 2 3 1 20 6 16 621 710
Wash. 3 6 2 - - 4 1 1 34 39
Oreg. 29 25 - - - - 2 2 42 40
Calif. 6 44 - 3 1 16 2 8 525 618
Alaska 4 18 - - - - 1 5 4 7
Hawaii 6 7 - - - - - - 16 6
Guam - - - - - - - - - 2
P.R. - - - - - - - - 15 53
V.I. - - - - - - - - - -
Amer. Samoa U U U U U U U U U U
C.N.M.I. - U - U - U - U - U
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N: Not notifiable. U: Unavailable. -: No reported cases.
* Incidence data for reporting years 2003 and 2004 are provisional and cumulative (year-to-date).
TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending July 31, 2004, and July 26, 2003
(30th Week)*
Hepatitis (viral, acute), by type
B C Legionellosis Listeriosis Lyme disease
Cum. Cum. Cum. Cum. Cum. Cum. Cum. Cum. Cum. Cum.
Reporting area 2004 2003 2004 2003 2004 2003 2004 2003 2004 2003
UNITED STATES 3,521 3,964 639 622 795 944 300 331 7,048 9,803
NEW ENGLAND 189 183 4 3 15 43 12 22 656 1,729
Maine 1 1 - - - 1 3 3 53 51
N.H. 23 11 - - 1 5 1 2 52 38
Vt. 3 2 1 3 1 1 - - 18 12
Mass. 102 129 3 - 4 22 3 12 189 962
R.I. 3 4 - - 2 2 1 - 80 121
Conn. 57 36 U U 7 12 4 5 264 545
MID. ATLANTIC 670 457 71 76 209 225 66 60 5,279 6,585
Upstate N.Y. 53 49 7 10 41 53 23 14 1,715 1,860
N.Y. City 58 139 - - 17 22 9 13 - 140
N.J. 387 115 - - 44 27 11 11 1,457 1,936
Pa. 172 154 64 66 107 123 23 22 2,107 2,649
E.N. CENTRAL 308 293 53 91 197 190 48 43 228 579
Ohio 77 84 5 7 101 96 19 11 49 28
Ind. 8 17 2 3 14 12 12 2 3 9
Ill. 50 38 9 14 10 25 - 12 - 42
Mich. 150 125 37 63 65 43 15 12 11 -
Wis. 23 29 - 4 7 14 2 6 165 500
W.N. CENTRAL 228 181 199 133 18 42 7 8 166 135
Minn. 28 21 8 5 1 3 3 2 96 87
Iowa 10 5 - 1 3 7 1 - 13 18
Mo. 154 127 191 126 12 20 2 3 48 25
N. Dak. 3 - - - 1 1 - - - -
S. Dak. - 2 - - 1 1 - - - -
Nebr. 18 15 - 1 - 2 1 3 6 2
Kans. 15 11 - - - 8 - - 3 3
S. ATLANTIC 1,068 1,102 105 99 194 262 50 62 617 624
Del. 22 6 - - 4 8 N N 66 106
Md. 90 70 13 6 36 66 6 9 382 399
D.C. 13 3 1 - 5 3 - - 2 4
Va. 123 97 14 4 23 50 10 7 56 39
W. Va. 18 12 17 1 4 8 1 3 2 6
N.C. 107 99 7 7 20 16 13 10 63 43
S.C. 54 93 7 23 1 5 - 2 5 1
Ga. 338 359 7 7 28 20 8 18 8 9
Fla. 303 363 39 51 73 86 12 13 33 17
E.S. CENTRAL 231 258 56 48 43 61 17 13 26 31
Ky. 31 43 18 8 18 23 4 2 11 7
Tenn. 101 104 21 11 15 20 8 3 9 8
Ala. 36 53 1 5 9 14 3 6 1 2
Miss. 63 58 16 24 1 4 2 2 5 14
W.S. CENTRAL 136 647 80 112 35 42 21 36 15 70
Ark. 31 52 1 3 - 2 1 1 2 -
La. 34 85 44 70 3 1 2 2 2 6
Okla. 23 38 3 2 2 4 - 1 - -
Tex. 48 472 32 37 30 35 18 32 11 64
MOUNTAIN 288 346 29 23 45 41 14 18 12 7
Mont. 2 8 2 1 1 2 - 1 - -
Idaho 6 4 - 1 6 3 1 1 2 2
Wyo. 7 22 - - 5 2 - - 2 -
Colo. 28 51 5 5 6 7 5 6 1 -
N. Mex. 9 25 7 - - 2 - 2 - 1
Ariz. 161 163 4 4 10 9 - 5 1 -
Utah 29 26 2 - 14 12 1 2 6 1
Nev. 46 47 9 12 3 4 7 1 - 3
PACIFIC 403 497 42 37 39 38 65 69 49 43
Wash. 32 40 13 11 6 5 6 4 4 -
Oreg. 65 74 10 7 N N 5 2 19 9
Calif. 290 365 16 18 33 33 52 59 26 32
Alaska 13 3 - - - - - - - 2
Hawaii 3 15 3 1 - - 2 4 N N
Guam - 4 - 3 - - - - - -
P.R. 36 78 - - 1 - - - N N
V.I. - - - - - - - - - -
Amer. Samoa U U U U U U U U U U
C.N.M.I. - U - U - U - U - U
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N: Not notifiable. U: Unavailable. - : No reported cases.
* Incidence data for reporting years 2003 and 2004 are provisional and cumulative (year-to-date).
TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending July 31, 2004, and July 26, 2003
(30th Week)*
Meningococcal Rocky Mountain
Malaria disease Pertussis Rabies, animal spotted fever
Cum. Cum. Cum. Cum. Cum. Cum. Cum. Cum. Cum. Cum.
Reporting area 2004 2003 2004 2003 2004 2003 2004 2003 2004 2003
UNITED STATES 651 627 877 1,089 6,114 4,155 2,993 4,032 554 325
NEW ENGLAND 48 26 44 50 761 455 313 295 11 4
Maine 5 1 8 5 2 9 31 27 - -
N.H. 1 3 3 3 26 26 11 14 - -
Vt. 3 - 2 - 43 44 11 18 - -
Mass. 24 13 25 31 662 349 128 101 9 4
R.I. 2 - 1 2 16 7 17 37 1 -
Conn. 13 9 5 9 12 20 115 98 1 -
MID. ATLANTIC 157 155 110 136 1,429 414 274 499 36 21
Upstate N.Y. 24 32 27 32 1,026 174 241 204 1 -
N.Y. City 67 78 20 31 76 59 4 5 5 7
N.J. 33 26 24 18 120 76 - 62 10 10
Pa. 33 19 39 55 207 105 29 228 20 4
E.N. CENTRAL 55 61 120 178 1,299 368 44 56 18 9
Ohio 18 11 46 45 281 132 17 21 10 4
Ind. 3 1 16 31 55 33 5 6 5 1
Ill. 10 29 12 49 226 32 14 7 - 2
Mich. 15 16 36 30 71 44 8 18 3 2
Wis. 9 4 10 23 666 127 - 4 - -
W.N. CENTRAL 45 28 59 80 632 185 281 398 63 27
Minn. 18 14 16 19 109 59 42 17 - 1
Iowa 2 3 11 16 36 46 41 52 - 2
Mo. 13 3 18 30 191 43 20 8 54 20
N. Dak. 3 1 1 1 250 3 40 38 - -
S. Dak. 1 2 2 1 9 3 10 88 3 2
Nebr. 2 - 2 6 4 5 53 69 6 2
Kans. 6 5 9 7 33 26 75 126 - -
S. ATLANTIC 172 152 168 192 323 294 1,137 1,635 254 197
Del. 3 - 19 8 5 5 9 23 - -
Md. 37 35 8 20 64 41 50 237 26 51
D.C. 8 7 4 4 2 - - - - -
Va. 15 17 10 19 99 60 274 323 11 11
W. Va. - 4 5 3 5 6 37 52 3 4
N.C. 11 12 24 24 49 79 372 469 174 78
S.C. 7 3 12 15 28 40 92 129 9 10
Ga. 34 36 10 21 10 20 159 214 17 38
Fla. 57 38 76 78 61 43 144 188 14 5
E.S. CENTRAL 19 13 36 51 75 89 70 126 61 54
Ky. 1 1 5 10 20 20 15 22 - -
Tenn. 3 4 11 13 37 46 24 85 25 30
Ala. 11 5 10 14 12 15 28 18 17 6
Miss. 4 3 10 14 6 8 3 1 19 18
W.S. CENTRAL 56 80 84 122 300 314 694 805 95 8
Ark. 6 4 14 10 15 23 31 25 65 -
La. 2 3 23 31 7 7 - 1 3 -
Okla. 2 3 5 12 17 37 73 141 27 2
Tex. 46 70 42 69 261 247 590 638 - 6
MOUNTAIN 28 17 43 55 595 573 85 88 11 5
Mont. - - 3 3 18 1 14 12 3 1
Idaho 1 1 6 6 20 40 1 3 1 1
Wyo. - 1 2 2 11 119 - 1 1 2
Colo. 9 11 10 13 302 202 15 14 - 1
N. Mex. 1 - 6 7 68 36 2 5 2 -
Ariz. 8 2 9 20 122 98 49 43 1 -
Utah 5 1 4 - 44 57 4 6 3 -
Nev. 4 1 3 4 10 20 - 4 - -
PACIFIC 71 95 213 225 700 1,463 95 130 5 -
Wash. 6 14 21 19 379 352 - - - -
Oreg. 12 7 45 35 258 293 2 5 3 -
Calif. 52 71 142 157 44 810 85 120 2 -
Alaska - - 1 4 8 1 8 5 - -
Hawaii 1 3 4 10 11 7 - - - -
Guam - - - - - 1 - - - -
P.R. - - 4 8 2 1 33 44 N N
V.I. - - - - - - - - - -
Amer. Samoa U U U U U U U U U U
C.N.M.I. - U - U - U - U - U
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N: Not notifiable. U: Unavailable. - : No reported cases.
* Incidence data for reporting years 2003 and 2004 are provisional and cumulative (year-to-date).
TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending July 31, 2004, and July 26, 2003
(30th Week)*
Streptococcus pneumoniae, invasive
Streptococcal disease, Drug resistant,
Salmonellosis Shigellosis invasive, group A all ages Age <5 years
Cum. Cum. Cum. Cum. Cum. Cum. Cum. Cum. Cum. Cum.
Reporting area 2004 2003 2004 2003 2004 2003 2004 2003 2004 2003
UNITED STATES 18,587 20,431 5,884 13,157 3,038 3,979 1,374 1,346 377 467
NEW ENGLAND 984 1,070 138 171 137 359 18 71 7 6
Maine 41 71 2 6 6 22 2 - 1 -
N.H. 51 83 5 5 15 23 - - N N
Vt. 32 38 2 5 8 16 7 6 1 3
Mass. 583 635 85 116 91 160 N N N N
R.I. 48 40 9 4 17 5 9 10 5 3
Conn. 229 203 35 35 - 133 - 55 U U
MID. ATLANTIC 2,891 2,449 679 1,400 519 697 99 90 75 68
Upstate N.Y. 610 514 310 191 171 266 46 48 51 49
N.Y. City 645 665 192 221 72 94 U U U U
N.J. 432 422 119 241 118 138 - - 4 2
Pa. 1,204 848 58 747 158 199 53 42 20 17
E.N. CENTRAL 2,105 3,016 393 1,122 617 976 322 310 107 204
Ohio 695 758 90 211 165 234 232 202 56 74
Ind. 212 291 87 79 70 93 90 108 22 19
Ill. 321 1,113 87 598 133 243 - - - 77
Mich. 453 416 64 158 213 281 N N N N
Wis. 424 438 65 76 36 125 N N 29 34
W.N. CENTRAL 1,316 1,169 223 407 208 238 11 11 55 53
Minn. 309 284 27 54 106 113 - - 38 37
Iowa 260 198 43 28 N N N N N N
Mo. 377 378 103 207 43 52 8 7 8 2
N. Dak. 19 23 2 6 9 12 - 3 2 4
S. Dak. 55 51 7 9 9 19 3 1 - -
Nebr. 86 81 11 63 10 22 - - 5 5
Kans. 210 154 30 40 31 20 N N 2 5
S. ATLANTIC 4,640 4,606 1,578 4,140 595 664 712 705 27 12
Del. 37 49 4 144 3 6 4 1 N N
Md. 468 420 76 341 124 165 - 6 16 -
D.C. 25 15 24 32 4 5 4 - 3 4
Va. 560 492 82 234 51 81 N N N N
W. Va. 105 63 3 - 17 30 82 50 8 8
N.C. 571 543 172 573 85 78 N N U U
S.C. 303 226 204 259 35 32 65 102 N N
Ga. 699 861 350 828 122 129 160 156 N N
Fla. 1,872 1,937 663 1,729 154 138 397 390 N N
E.S. CENTRAL 1,085 1,336 348 575 142 137 81 99 - -
Ky. 187 219 43 63 49 36 21 12 N N
Tenn. 223 388 130 201 93 101 60 87 N N
Ala. 326 315 143 189 - - - - N N
Miss. 349 414 32 122 - - - - - -
W.S. CENTRAL 1,557 2,949 1,338 3,528 170 181 36 52 73 72
Ark. 264 325 37 59 12 6 6 17 7 4
La. 274 414 170 276 2 1 30 35 12 14
Okla. 191 213 281 507 43 58 N N 30 35
Tex. 828 1,997 850 2,686 113 116 N N 24 19
MOUNTAIN 1,258 1,128 422 548 344 337 23 4 33 52
Mont. 79 54 4 2 - 1 - - - -
Idaho 98 101 7 13 6 14 N N N N
Wyo. 29 51 1 3 6 2 6 3 - -
Colo. 304 279 73 98 92 92 - - 30 40
N. Mex. 119 113 60 109 59 84 5 - - 8
Ariz. 406 336 230 267 151 121 N N N N
Utah 127 106 24 27 28 22 10 1 3 4
Nev. 96 88 23 29 2 1 2 - - -
PACIFIC 2,751 2,708 765 1,266 306 390 72 4 - -
Wash. 260 318 58 104 34 41 - - N N
Oreg. 225 240 39 87 N N N N N N
Calif. 2,026 1,990 639 1,052 216 281 N N N N
Alaska 38 50 4 4 - - - - N N
Hawaii 202 110 25 19 56 68 72 4 - -
Guam - 28 - 23 - - - - - -
P.R. 105 364 1 9 N N N N N N
V.I. - - - - - - - - - -
Amer. Samoa U U U U U U U U U U
C.N.M.I. 3 U - U - U - U - U
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N: Not notifiable. U: Unavailable. - : No reported cases.
* Incidence data for reporting years 2003 and 2004 are provisional and cumulative (year-to-date).
TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending July 31, 2004, and July 26, 2003
(30th Week)*
Syphilis Varicella
Primary & secondary Congenital Tuberculosis Typhoid fever (Chickenpox)
Cum. Cum. Cum. Cum. Cum. Cum. Cum. Cum. Cum. Cum.
Reporting area 2004 2003 2004 2003 2004 2003 2004 2003 2004 2003
UNITED STATES 4,104 4,046 195 259 5,477 7,115 140 184 9,505 10,426
NEW ENGLAND 113 126 1 - 207 231 15 17 587 2,159
Maine 2 6 - - - 11 - - 179 639
N.H. 3 15 - - 9 10 - 1 - -
Vt. - - - - - 5 - - 408 489
Mass. 75 81 - - 128 111 12 9 - 108
R.I. 14 12 - - 19 31 1 2 - 3
Conn. 19 12 1 - 51 63 2 5 - 920
MID. ATLANTIC 548 475 31 41 1,161 1,239 34 32 60 15
Upstate N.Y. 48 20 2 6 136 139 3 4 - -
N.Y. City 332 269 10 23 596 662 11 18 - -
N.J. 95 96 19 12 235 236 9 9 - -
Pa. 73 90 - - 194 202 11 1 60 15
E.N. CENTRAL 448 557 34 44 667 633 6 22 3,893 3,764
Ohio 128 118 1 2 114 111 2 - 1,019 924
Ind. 35 31 8 9 72 74 - 4 - -
Ill. 157 224 3 16 305 292 - 11 - -
Mich. 112 170 22 17 130 119 3 7 2,527 2,260
Wis. 16 14 - - 46 37 1 - 347 580
W.N. CENTRAL 93 97 2 4 242 265 6 4 122 39
Minn. 14 32 - - 95 98 3 2 - -
Iowa 5 7 - - 19 16 - 1 N N
Mo. 54 33 1 4 68 71 2 1 5 -
N. Dak. - 1 - - 3 - - - 74 39
S. Dak. - 1 - - 5 16 - - 43 -
Nebr. 4 3 - - 15 11 1 - - -
Kans. 16 20 1 - 37 53 - - - -
S. ATLANTIC 1,103 1,065 25 48 1,061 1,355 28 33 1,527 1,519
Del. 4 4 1 - - - - - 4 16
Md. 220 169 3 8 141 131 9 8 - -
D.C. 46 32 1 - 43 - - - 17 22
Va. 63 55 2 1 119 130 2 11 378 424
W. Va. 2 1 - - 13 11 - - 903 889
N.C. 104 93 6 10 139 167 3 5 N N
S.C. 65 65 1 4 112 86 - - 225 168
Ga. 160 287 1 12 11 291 9 4 - -
Fla. 439 359 10 13 483 539 5 5 - -
E.S. CENTRAL 230 186 16 10 330 387 5 4 - -
Ky. 26 24 1 1 55 68 2 - - -
Tenn. 79 77 7 2 127 125 3 1 - -
Ala. 102 67 6 5 115 133 - 3 - -
Miss. 23 18 2 2 33 61 - - - -
W.S. CENTRAL 663 478 29 45 456 1,084 7 13 1,741 2,573
Ark. 26 30 - 1 69 57 - - - -
La. 136 66 - 1 - - - - 42 9
Okla. 19 30 2 1 83 82 - - - -
Tex. 482 352 27 42 304 945 7 13 1,699 2,564
MOUNTAIN 195 188 35 24 261 220 5 4 1,575 357
Mont. - - - - 4 5 - - - -
Idaho 13 4 2 1 4 5 - - - -
Wyo. 1 - - - 2 2 - - 22 37
Colo. 19 23 - 3 58 53 1 3 1,184 -
N. Mex. 26 36 1 4 14 29 - - 68 -
Ariz. 116 115 32 16 117 87 2 1 - -
Utah 4 2 - - 26 18 1 - 301 320
Nev. 16 8 - - 36 21 1 - - -
PACIFIC 711 874 22 43 1,092 1,701 34 55 - -
Wash. 62 42 - - 136 141 3 2 - -
Oreg. 18 29 - - 46 63 1 2 - -
Calif. 628 796 22 43 828 1,404 24 51 - -
Alaska - 1 - - 18 34 - - - -
Hawaii 3 6 - - 64 59 6 - - -
Guam - 1 - - - 38 - - - 90
P.R. 71 117 3 8 14 58 - - 171 377
V.I. 4 1 - - - - - - - -
Amer. Samoa U U U U U U U U U U
C.N.M.I. 2 U - U 10 U - U - U
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U: Unavailable.          -:No reported cases.
* Mortality data in this table are voluntarily reported from 122 cities in the United States, most of which have populations of >100,000. A death is reported by the place of its
occurrence and by the week that the death certificate was filed. Fetal deaths are not included.
† Pneumonia and influenza.
§ Because of changes in reporting methods in this Pennsylvania city, these numbers are partial counts for the current week. Complete counts will be available in 4 to 6 weeks.
¶ Total includes unknown ages.
NEW ENGLAND 501 353 94 29 16 9 43
Boston, Mass. 117 77 23 6 6 5 10
Bridgeport, Conn. 37 24 5 7 - 1 3
Cambridge, Mass. 21 17 2 1 1 - 2
Fall River, Mass. 14 10 4 - - - 2
Hartford, Conn. 48 32 9 5 2 - 2
Lowell, Mass. 26 20 5 1 - - 1
Lynn, Mass. 10 9 1 - - - -
New Bedford, Mass. 36 27 8 1 - - 5
New Haven, Conn. 42 27 8 4 2 1 4
Providence, R.I. 50 35 12 1 1 1 2
Somerville, Mass. 3 2 1 - - - -
Springfield, Mass. 28 23 3 - 1 1 8
Waterbury, Conn. 19 15 2 1 1 - -
Worcester, Mass. 50 35 11 2 2 - 4
MID. ATLANTIC 2,046 1,366 462 144 34 38 113
Albany, N.Y. 59 40 10 4 2 3 2
Allentown, Pa. 23 21 2 - - - -
Buffalo, N.Y. 79 62 9 5 1 2 7
Camden, N.J. 28 10 12 3 2 1 3
Elizabeth, N.J. 17 14 1 2 - - 3
Erie, Pa. 46 34 9 2 1 - 1
Jersey City, N.J. 26 19 4 2 - 1 -
New York City, N.Y. 988 638 235 74 18 21 41
Newark, N.J. 39 19 12 6 1 1 2
Paterson, N.J. 11 5 4 2 - - -
Philadelphia, Pa. 391 258 91 32 7 3 21
Pittsburgh, Pa.§ 27 19 6 1 1 - 3
Reading, Pa. 21 13 5 2 - 1 2
Rochester, N.Y. 127 90 30 4 1 2 11
Schenectady, N.Y. 22 20 1 1 - - 4
Scranton, Pa. 30 24 6 - - - -
Syracuse, N.Y. 71 54 11 3 - 3 12
Trenton, N.J. 9 5 4 - - - -
Utica, N.Y. 14 9 4 1 - - 1
Yonkers, N.Y. 18 12 6 - - - -
E.N. CENTRAL 2,047 1,316 455 172 55 49 117
Akron, Ohio 44 31 7 5 1 - 4
Canton, Ohio 35 26 4 5 - - 4
Chicago, Ill. 367 204 107 37 12 7 23
Cincinnati, Ohio 93 53 22 10 6 2 6
Cleveland, Ohio 228 164 42 10 8 4 5
Columbus, Ohio 218 148 47 16 4 3 19
Dayton, Ohio 123 80 30 11 1 1 11
Detroit, Mich. 177 95 54 23 - 5 7
Evansville, Ind. 45 34 9 1 1 - 4
Fort Wayne, Ind. 65 42 17 5 1 - 4
Gary, Ind. 16 9 4 2 1 - -
Grand Rapids, Mich. 47 32 7 2 2 4 5
Indianapolis, Ind. 193 111 39 21 8 14 6
Lansing, Mich. 39 28 8 1 2 - -
Milwaukee, Wis. 84 59 14 7 1 3 7
Peoria, Ill. 32 24 4 3 1 - 1
Rockford, Ill. 51 35 13 1 2 - 4
South Bend, Ind. 41 32 2 4 2 1 2
Toledo, Ohio 93 69 13 5 2 4 4
Youngstown, Ohio 56 40 12 3 - 1 1
W.N. CENTRAL 710 446 170 55 23 14 53
Des Moines, Iowa 72 57 11 2 - 2 5
Duluth, Minn. 30 26 4 - - - 1
Kansas City, Kans. 23 10 8 2 3 - 2
Kansas City, Mo. 94 58 28 5 2 1 3
Lincoln, Nebr. 32 26 4 2 - - 4
Minneapolis, Minn. 59 37 12 3 4 3 7
Omaha, Nebr. 67 42 16 5 2 2 6
St. Louis, Mo. 180 86 55 23 11 3 12
St. Paul, Minn. 41 32 6 2 1 - 3
Wichita, Kans. 112 72 26 11 - 3 10
S. ATLANTIC 1,337 839 320 114 34 28 52
Atlanta, Ga. 163 94 46 15 7 1 3
Baltimore, Md. 201 115 49 23 10 3 11
Charlotte, N.C. 113 65 32 11 1 4 7
Jacksonville, Fla. 121 73 32 11 1 4 3
Miami, Fla. 104 66 29 5 3 1 5
Norfolk, Va. 64 39 8 9 5 3 3
Richmond, Va. 60 33 21 4 2 - 4
Savannah, Ga. 58 38 15 4 - 1 1
St. Petersburg, Fla. 50 38 10 1 - 1 3
Tampa, Fla. 185 127 39 14 2 3 9
Washington, D.C. 200 136 38 16 3 6 2
Wilmington, Del. 18 15 1 1 - 1 1
E.S. CENTRAL 818 528 173 68 32 16 58
Birmingham, Ala. 156 104 33 10 5 3 10
Chattanooga, Tenn. 71 51 12 3 5 - 6
Knoxville, Tenn. 94 62 19 8 3 2 5
Lexington, Ky. 99 68 19 4 7 1 9
Memphis, Tenn. 184 115 42 19 4 4 15
Mobile, Ala. 58 36 11 5 4 2 2
Montgomery, Ala. 25 16 6 3 - - 2
Nashville, Tenn. 131 76 31 16 4 4 9
W.S. CENTRAL 1,466 912 341 122 57 34 73
Austin, Tex. 87 58 17 9 1 2 1
Baton Rouge, La. 52 32 13 5 1 1 -
Corpus Christi, Tex. 47 32 10 1 2 2 6
Dallas, Tex. 171 97 39 16 9 10 10
El Paso, Tex. 68 38 21 3 4 2 1
Ft. Worth, Tex. 162 104 33 12 9 4 5
Houston, Tex. 395 253 92 33 13 4 25
Little Rock, Ark. 65 39 16 7 - 3 7
New Orleans, La. 53 25 19 9 - - -
San Antonio, Tex. 216 138 44 19 13 2 13
Shreveport, La. 35 20 10 2 2 1 2
Tulsa, Okla. 115 76 27 6 3 3 3
MOUNTAIN 931 577 215 85 29 23 43
Albuquerque, N.M. 102 63 21 14 3 1 4
Boise, Idaho U U U U U U U
Colo. Springs, Colo. 85 53 15 11 5 1 4
Denver, Colo. 102 54 30 10 2 6 4
Las Vegas, Nev. 228 137 62 21 4 3 9
Ogden, Utah 34 24 8 1 - 1 1
Phoenix, Ariz. 68 40 15 10 - 2 5
Pueblo, Colo. 36 26 6 1 3 - 2
Salt Lake City, Utah 146 92 32 10 6 6 10
Tucson, Ariz. 130 88 26 7 6 3 4
PACIFIC 1,645 1,167 303 97 45 33 136
Berkeley, Calif. 12 7 3 1 - 1 1
Fresno, Calif. 103 74 18 9 1 1 1
Glendale, Calif. 22 17 3 2 - - 5
Honolulu, Hawaii 89 67 16 1 2 3 6
Long Beach, Calif. 56 39 9 4 2 2 3
Los Angeles, Calif. 348 249 69 17 8 5 43
Pasadena, Calif. 23 19 1 2 - 1 5
Portland, Oreg. 128 92 24 7 3 2 4
Sacramento, Calif. 161 114 27 12 6 2 10
San Diego, Calif. 154 110 36 4 2 2 17
San Francisco, Calif. 131 85 22 12 7 5 9
San Jose, Calif. 191 130 33 14 9 5 19
Santa Cruz, Calif. U U U U U U U
Seattle, Wash. 83 57 15 8 1 2 5
Spokane, Wash. 51 38 8 1 3 1 5
Tacoma, Wash. 93 69 19 3 1 1 3
TOTAL 11,501¶ 7,504 2,533 886 325 244 688
TABLE III. Deaths in 122 U.S. cities,* week ending July 31, 2004 (30th Week)
All causes, by age (years) All causes, by age (years)
All P&I† All P&I†
Reporting Area Ages >65 45-64 25-44 1-24 <1 Total Reporting Area Ages >65 45-64 25-44 1-24 <1 Total
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